Stephan Mielke

Publikationer
Forskningsbidrag
Populärvetenskap och samverkan

Artiklar

Article: AMERICAN JOURNAL OF HEMATOLOGY. 2025;100(1):38-51
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT
Luft T; Gras L; Koster L; Kroeger N; Schroeder T; Platzbecker U; Sockel K; de Latour RP; Stelljes M; Sengeloev H; Eder M; Blau IW; Dreger P; Yakoub-Agha I; Maertens J; Salmenniemi U; Bethge W; Mielke S; Kobbe G; Pouli A; de Wreede LC; Raj K; Drozd-Sokolowska J; Mclornan DP; Robin M
Article: LEUKEMIA. 2024;:1-7
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
Orti G; Peczynski C; Boreland W; O'Reilly M; von Bonin M; Balduzzi A; Besley C; Kalwak K; Ryhaenen S; Guengoer T; Wynn RF; Bader P; Mielke S; Blaise D; Amrolia P; Yakoub-Agha I; Calkoen F; Schubert M-L; Potter V; Pichler H; Kroeger N; Kwon M; Sengeloev H; Torrent A; Chalandon Y; van Gorkom G; Koenecke C; Graham C; Schoemans H; Moiseev I; Penack O; Peric Z
Article: BONE MARROW TRANSPLANTATION. 2024;:1-9
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Sever M; Drozd-Sokolowska J; Gras L; Koster L; Folber F; Mielke S; Fenk R; Basak G; Apperley J; Byrne J; Rambaldi A; Ringhoffer M; Eder M; Trneny M; Blaise D; Lenhoff S; Isaksson C; Passweg J; Partanen A; Sakellari I; Schoenland S; Morris C; Beksac M; Raj K; Hayden PJ; McLornan DP
Article: EBIOMEDICINE. 2024;109:105385
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Gao Y; Soderdahl G; Osterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; Aberg M; Lore K; Chen MS; Ljungman P; Buggert M; Aleman S; Ljunggren H-G
Article: BONE MARROW TRANSPLANTATION. 2024;59(10):1402-1412
Adenovirus infections after allogeneic hematopoietic cell transplantation in children and adults: a study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
Styczynski J; Tridello G; Knelange N; Wendel L; Ljungman P; Mikulska M; Gil L; Cesaro S; Averbuch D; von dem Borne P; Xhaard A; Mielke S; Neven B; Snowden JA; Dalle J-H; Rubio MT; Crawley C; Maertens J; Kuball J; Chevallier P; Michel G; Gabriel M; Burns D; Wynn RF; Renard C; Blijlevens N; Jubert C; Gedde-Dahl T; Collin M; Labussiere-Wallet H; Kalwak K; Broers AEC; Yakoub-Agha I; Itala-Remes M; de la Camara R
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2024;99(9):1732-1745
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler A; Ngoya M; Galimard J-E; Labopin M; Blau IW; Kroeger N; Gedde-Dahl T; Schroeder T; Burns D; Salmenniemi U; Rambaldi A; Choi G; de Latour RP; Vydra J; Sengeloev H; Eder M; Mielke S; Forcade E; Kulagin A; Ciceri F; Mohty M
Article: LEUKEMIA. 2024;38(9):1985-1991
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
Spanjaart AM; Ljungman P; Tridello G; Schwartz J; Martinez-Cibrian N; Barba P; Kwon M; Lopez-Corral L; Martinez-Lopez J; Ferra C; Di Blasi R; Ghesquieres H; Mutsaers P; Calkoen F; Jak M; van Doesum J; Vermaat JSP; van der Poel M; Maertens J; Gambella M; Metafuni E; Ciceri F; Saccardi R; Nicholson E; Tholouli E; Matthew C; Potter V; Bloor A; Besley C; Roddie C; Wilson K; Nagler A; Campos A; Petersen SL; Folber F; Bader P; Finke J; Kroger N; Knelange N; de la Camara R; Kersten MJ; Mielke S
Article: NATURE MEDICINE. 2024;30(8):2199-2207
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Morschhauser F; Dahiya S; Palomba ML; Garcia-Sancho AM; Ortega JLR; Kuruvilla J; Jaeger U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Kumar J; Nastoupil LJ
Article: CANCER. 2024;130(15):2642-2651
Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study
Loke J; Labopin M; Craddock C; Socie G; Gedde-Dahl T; Blaise D; Forcade E; Salmenniemi U; Huynh A; Versluis J; Yakoub-Agha I; Labussiere-Wallet H; Maertens J; Passweg J; Bulabois CE; Gabellier L; Mielke S; Castilla-Llorente C; Deconinck E; Brissot E; Nagler A; Ciceri F; Mohty M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2024;:S2666-6367(24)00547-5
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT.
Giebel S; Labopin M; Peric Z; Passweg J; Blaise D; Salmenniemi U; Beauvais D; Reményi P; Chevallier P; Mielke S; Gedde-Dahl T; Cornelissen JJ; Balsat M; Bug G; Bazarbachi A; Brissot E; Nagler A; Ciceri F; Mohty M
Article: BLOOD. 2024;144(3):323-333
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
Montoro J; Eikema D-J; Tuffnell J; Potter V; Kalwak K; Halkes CJM; Kulagin A; Collin M; Wynn RF; Robinson S; Nicholson E; Sengeloev H; Clay J; Halahleh K; Skorobogatova E; Sanz J; Passweg J; Mielke S; Ryhaenen S; Carpenter B; Gedde-Dahl T; Tholouli E; Fanin R; Lewalle P; Kulasekararaj A; Risitano A; de Latour RP
Article: BONE MARROW TRANSPLANTATION. 2024;59(7):1012-1021
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler A; Labopin M; Swoboda R; Schroeder T; Hamladji R-M; Griskevicius L; Salmenniemi U; Rambaldi A; Mielke S; Kulagin A; Passweg J; Luft T; Gedde-Dahl T; Forcade E; Helbig G; Stelljes M; Castilla-Llorente C; Spyridonidis A; Brissot E; Ciceri F; Mohty M
Article: LEUKEMIA. 2024;38(5):1156-1163
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Penack O; Abouqateb M; Peczynski C; Boreland W; Kroeger N; Stelljes M; Gedde-Dahl T; Blau IW; Schroeder T; Salmenniemi U; Kulagin A; de Latour RP; Mielke S; Zeiser R; Moiseev I; Schoemans H; Koenecke C; Peric Z
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(12):1378-1390
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Lundstrom LY; von Bahr L; Baltzer-Sollander K; Jadersten M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellstrom-Lindberg E
Article: CELL HOST AND MICROBE. 2024;32(2):156-161.e3
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Muller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Soderdahl G; Smith CIE; Lore K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren H-G; Osterborg A; Sette A; Grifoni A; Aleman S; Buggert M
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2024;30(2):s258-s259
Post-Transplant Cyclophosphamide, Tacrolimus (TAC) or Cyclosporine a and Mycophenolate Mofetil Versus Anti-Thymocyte Globulin, TAC, Methotrexate Combinations As Graft-versus-Host Disease Prophylaxis Post Allogeneic Stem Cell Transplantation from Sibling and Unrelated Donors in Patients with Acute Myeloid Leukemia: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler A; Labopin M; Schroeder T; Hamladji R-M; Griskevicius L; Rambaldi A; Mielke S; Kulagin A; Passweg J; Dreger P; Gedde-Dahl T; Forcade E; Helbig G; Stelljes M; Castilla-Llorente C; Spyridonidis A; Savani BN; Brissot E; Ciceri F; Mohty M
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2024;30(2):s46-s47
Relapse Incidence Post Unrelated Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide (PTCy) in Patients with Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler A; Ngoya M; Galimard J-E; Labopin M; Blau W-I; Kroger N; Gedde-Dahl T; Schroeder T; Burns D; Salmenniemi U; Rambaldi A; Choi G; de Latour RP; Vydra J; Sengeloev H; Eder M; Mielke S; Forcade E; Bondarenko SN; Ciceri F; Mohty M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2024;30(1):95.e1-95.e10
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Battipaglia G; Labopin M; Mielke S; Ruggeri A; Ozkurt ZN; Bourhis JH; Rabitsch W; Yakoub-Agha I; Grillo G; Sanz J; Arcese W; Novis Y; Fegueux N; Spyridonidis A; Giebel S; Nagler A; Ciceri F; Mohty M
Article: ECLINICALMEDICINE. 2024;67:102393
Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party
Penack O; Tridello G; Salmenniemi U; Martino R; Khanna N; Perruccio K; Fagioli F; Richert-Przygonska M; Labussiere-Wallet H; Maertens J; Jubert C; Aljurf M; Pichler H; Krivan G; Kunadt D; Popova M; Gabriel M; Calore E; Blau IW; Benedetti F; Itala-Remes M; de Kort E; Russo D; Faraci M; Menard A-L; von dem Borne P; Poire X; Yesilipek A; Gozdzik J; Yegin ZA; Yanez L; Facchini L; Van Gorkom G; Thurner L; Kocak U; Sampol A; Zuckerman T; Bierings M; Mielke S; Ciceri F; Wendel L; Knelange N; Mikulska M; Averbuch D; Styczynski J; de la Camara R; Cesaroaq S
Journal article: OPEN FORUM INFECTIOUS DISEASES. 2023;10(Supplement_2):ofad500.555
485. Improved Outcome of COVID-19 in CAR T Cell Treated Patients; results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Ljungman P; Spanjaart AM; Tridello G; Knelange N; de la Camara R; Kersten MJ; Mielke S
Journal article: BLOOD. 2023;142:472
Conditioning Intensity in Patients Aged > 50 Years Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrom: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Loukili NH; Luuk GS; Koster L; Blaise D; Gedde-Dahl T; Maertens J; De latour RP; Sengeloev H; Mielke S; Chevallier P; Passweg JR; Byrne JL; Salmenniemi U; Sirvent A; Guyotat D; Sica S; de Wreede LC; Onida F; Scheid C; Gurnari C; Drozd-Sokolowska J; Raj K; Robin M; McLornan DP; Yakoub-Agha I
Journal article: BLOOD. 2023;142:237
Relapse Incidence Post Unrelated Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide (PTCy) Versus Conventional Anti-Graft Versus Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler A; Ngoya M; Galimard J-E; Labopin M; Blau IW; Kroeger N; Gedde-Dahl T; Schroeder T; Burns D; Salmenniemi U; Rambaldi A; Choi G; De latour RP; Vydra J; Sengeloev H; Eder M; Mielke S; Forcade E; Bondarenko S; Ciceri F; Mohty M
Journal article: BLOOD. 2023;142:895
Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT
Pagliuca S; Mooyaart J; Kroger N; Finke J; Potter V; Dreger P; Hilgendorf I; Bethge WA; De latour RP; Rambaldi A; Sengeloev H; Passweg J; Gedde-Dahl T; Burns D; Orchard K; Mielke S; Edinger M; Andreani M; Crivello P; Merli P
Journal article: BLOOD. 2023;142:3558
ATG or Post-Transplant Cyclophosphamide to Prevent Gvhd in Matched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party
Penack O; Abouqateb M; Peczynski C; Boreland W; Kroeger N; Stelljes M; Gedde-Dahl T; Blau IW; Schroeder T; Salmenniemi U; Aleksandr KS; De Latour RP; Mielke S; Finke J; Moiseev IS; Schoemans H; Koenecke C; Peric Z
Journal article: BLOOD. 2023;142:2181
Post-Transplant Cyclophosphamide, Tacrolimus or Cyclosporine a and Mycophenolate Mofetil Compared to Anti-Thymocyte Globulin tacrolimus or Cyclosporine a and Methotrexate Combinations As Graft- versus -Host Disease Prophylaxis Post Allogeneic Stem Cell Transplantation from Sibling and Unrelated Donors in Patients with Acute Myeloid Leukemia: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler A; Labopin M; Schroeder T; Hamladji R-M; Griskevicius L; Salmenniemi U; Rambaldi A; Mielke S; Aleksandr KS; Passweg JR; Dreger P; Gedde-Dahl T; Forcade E; Helbig G; Stelljes M; Castilla-Llorente C; Spyridonidis A; Savani BN; Brissot E; Ciceri F; Mohty M
Journal article: BLOOD. 2023;142:3592
Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma
Gagelmann N; Garderet L; Iacobelli S; Koster L; Carotti A; Schoenland S; Galieni P; Daskalakis M; Roeloffzen W; Hunter H; Duchosal MA; Lenhoff S; Arat M; Wulf GG; Bolam S; Pastore D; Gedde-Dahl T; Richardson DS; Mielke S; Raj K; Drozd-Sokolowska J; Hayden PJ; McLornan DP
Journal article: BLOOD. 2023;142:602
TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma
Morschhauser F; Dahiya S; Palomba ML; Garcia-Sancho AM; Reguera JL; Kuruvilla J; Jaeger U; Cartron G; Izutsu K; Dreyling M; Kahl BS; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Nastoupil LJ
Journal article: BLOOD. 2023;142:2189
Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study
Orti G; Peczynski C; Koenecke C; Boreland W; O'Reilly M; Bornhaeuser M; Balduzzi A; Besley C; Kalwak K; Samppa RS; Gungor T; Wynn RF; Bader P; Mielke S; Blaise D; Amrolia P; Yakoub-Agha I; Calkoen FGJ; Schubert M-L; Potter V; Holter W; Kroeger N; Kwon M; Sengeloev H; Schoemans H; Moiseev IS; Penack O; Peric Z
Journal article: BLOOD. 2023;142:1047
Alternative Donor Transplantation for Severe Aplastic Anemia: A Comparative Study of the Saawp EBMT
Montoro J; Dirk-Jan ES; Joe TS; Potter V; Krzysztof KS; Stijn HS; Aleksandr KS; Matthew CPS; Robert WS; Stephen RJ; Emma NS; Sengeloev H; Jennifer CS; Khaled HS; Elena SS; Jakob PS; Mielke S; Samppa RS; Carpenter B; Gedde-Dahl T; Tholouli E; Fanin R; Philippe LS; Kulasekararaj A; Risitano AM; De Latour RP
Article: BLOOD. 2023;142(10):865-877
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Rejeski K; Subklewe M; Aljurf M; Bachy E; Balduzzi A; Barba P; Bruno B; Benjamin R; Carrabba MG; Chabannon C; Ciceri F; Corradini P; Delgado J; Di Blasi R; Greco R; Houot R; Iacoboni G; Jager U; Kersten MJ; Mielke S; Nagler A; Onida F; Peric Z; Roddie C; Ruggeri A; Sanchez-Guijo F; Sanchez-Ortega I; Schneidawind D; Schubert M-L; Snowden JA; Thieblemont C; Topp M; Zinzani PL; Gribben JG; Bonini C; Sureda A; Yakoub-Agha I
Article: EBIOMEDICINE. 2023;94:104700
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; oesterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; aberg M; Lore K; Chen MS; Buggert M; Ljungman P; Aleman S; Ljunggren H-G
Article: SCIENCE ADVANCES. 2023;9(30):eadd6997
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Li L; Mohanty V; Dou J; Huang Y; Banerjee PP; Miao Q; Lohr JG; Vijaykumar T; Frede J; Knoechel B; Muniz-Feliciano L; Laskowski TJ; Liang S; Moyes JS; Nandivada V; Basar R; Kaplan M; Daher M; Liu E; Li Y; Acharya S; Lin P; Shanley M; Rafei H; Marin D; Mielke S; Champlin RE; Shpall EJ; Chen K; Rezvani K
Article: SCIENCE TRANSLATIONAL MEDICINE. 2023;15(704):eadg9452
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Muller TRR; Sekine T; Trubach D; Niessl J; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Olofsson A; Hernandez SPA; Gao Y; Cai C; Soderdahl G; Smith CIE; Osterborg A; Lore K; Sallberg Chen M; Ljungman P; Ljunggren H-G; Karlsson ACC; Saini SK; Aleman S; Buggert M
Article: BONE MARROW TRANSPLANTATION. 2023;58(7):791-800
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT
Nagler A; Labopin M; Mielke S; Passweg J; Blaise D; Gedde-Dahl T; Cornelissen JJJ; Salmenniemi U; Yakoub-Agha I; Remenyi P; Socie G; van Gorkom G; Labussiere-Wallet H; Huang X-J; Rubio MT; Byrne J; Craddock C; Griskevicius L; Ciceri F; Mohty M
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):877-880
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Morschhauser F; Dahiya S; Palomba ML; Garcia‐Sancho AM; Ortega JLR; Kuruvilla J; Jager U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Nastoupil LJ
Article: BONE MARROW TRANSPLANTATION. 2023;58(6):710-716
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
Bug G; Labopin M; Niittyvuopio R; Stelljes M; Reinhardt HC; Hilgendorf I; Kroeger N; Kaare A; Bethge W; Schaefer-Eckart K; Verbeek M; Mielke S; Carlson K; Bazarbachi A; Spyridonidis A; Savani BN; Nagler A; Mohty M
Journal article: JOURNAL OF IMMUNOLOGY. 2023;210(1_Supplement):75.16
Anamnestic expansion of Omicron-reactive CD8 +T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states
Müller TR; Sekine T; Trubach D; Niessl J; Olofsson A; Gao Y; Cai C; Nowak P; Blennow O; Hansson L; Mielke S; Bergman P; Ljunggren H-G; Karlsson AC; Saini SK; Aleman S; Buggert M
Article: BLOOD. 2023;141(14):1675-1684
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2023;29(2):s36-s37
44 Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Kamdar M
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2023;98(1):112-121
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
Chalandon Y; Sbianchi G; Gras L; Koster L; Apperley J; Byrne J; Salmenniemi U; Sengeloev H; Aljurf M; Helbig G; Kinsella F; Choi G; Remenyi P; Snowden JA; Robin M; Lenhoff S; Mielke S; Passweg J; Broers AEC; Kroeger N; Yegin ZA; Tan SM; Hayden PJ; McLornan DP; Yakoub-Agha I
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1125824
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Ljungman P; Tridello G; Pinana JL; Ciceri F; Sengeloev H; Kulagin A; Mielke S; Yegin ZA; Collin M; Einardottir S; Lepretre SD; Maertens J; Campos A; Metafuni E; Pichler H; Folber F; Solano C; Nicholson E; Yuksel MK; Carlson K; Aguado B; Besley C; Byrne J; Heras I; Dignan F; Kroger N; Robin C; Khan A; Lenhoff S; Grassi A; Dobsinska V; Miranda N; Jimenez M-J; Yonal-Hindilerden I; Wilson K; Averbuch D; Cesaro S; Xhaard A; Knelange N; Styczynski J; Mikulska M; de la Camara R
Article: BONE MARROW TRANSPLANTATION. 2022;57(12):1803-1809
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Gavriilaki E; Labopin M; Sakellari I; Salmenniemi U; Yakoub-Agha I; Potter V; Berceanu A; Rambaldi A; Hilgendorf I; Kroeger N; Mielke S; Zuckerman T; Sanz J; Busca A; Ozdogu H; Anagnostopoulos A; Savani B; Giebel S; Bazarbachi A; Spyridonidis A; Nagler A; Mohty M
Article: HEMASPHERE. 2022;6(11):e788
CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Salmenniemi U; Mielke S; Chevallier P; Rubio MT; Balsat M; Pioltelli P; Menard A-L; Socie G; Huynh A; Schaap N; Rodriguez AB; Cornelissen JJ; Yakoub-Agha I; Aljurf M; Giebel S; Brissot E; Peric Z; Nagler A; Mohty M
Article: EJHAEM. 2022;3(4):1277-1286
Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage-specific chimerism analysis
Lindahl H; Valentini D; Vonlanthen S; Sundin M; Bjorklund AT; Mielke S; Hauzenberger D
Article: BLOOD CANCER JOURNAL. 2022;12(9):140
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Raj K; Eikema D-J; Sheth V; Koster L; de Wreede LC; Blaise D; Di Grazia C; Koc Y; Potter V; Chevallier P; Lopez-Corral L; Wu D; Mielke S; Maertens J; Meijer E; Huynh A; Passweg J; Luft T; Perez-Simon JA; Ciceri F; Piekarska A; Hayri Ozsan G; Kroeger N; Robin M; Yakoub-Agha I
Article: IMMUNITY. 2022;55(9):1732-1746.e5
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Gao Y; Cai C; Wullimann D; Niessl J; Rivera-Ballesteros O; Chen P; Lange J; Cuapio A; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Perez-Potti A; Sekine T; Muller TR; Boulouis C; Kammann T; Parrot T; Muvva JR; Sobkowiak M; Healy K; Bogdanovic G; Muschiol S; Soderdahl G; Osterborg A; Hellgren F; Grifoni A; Weiskopf D; Sette A; Lore K; Chen MS; Ljungman P; Sandberg JK; Smith CIE; Bergman P; Ljunggren H-G; Aleman S; Buggert M
Journal article: HEMASPHERE. 2022;6:139-140
S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT
Nagler A; Labopin M; Mielke S; Passweg J; Blaise D; Gedde‐Dahl T; Cornelissen JJ; Salmenniemi U; Yakoub‐Agha I; Reményi P; Socié G; Van Gorkom G; Labussière‐Wallet H; Huang X; Rubio MT; Byrne JL; Craddock C; Griskevicius L; Ciceri F; Mohty M
Journal article: HEMASPHERE. 2022;6:68-69
S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Sollander K; Ejerblad E; Kittang AO; Olesen G; Werlenius O; Björklund A; Wiggh J; lindholm C; Lorentz F; Rasmussen B; Cammenga J; Weber D; Grönnås D; Dimitriou M; Kytölä S; Walldin G; Ljungman P; Groenbeck K; Mielke S; Jacobsen SE; Ebeling F; Cavelier L; Friis LS; Dybedal I; Hellström‐Lindberg E
Article: THE LANCET. 2022;399(10343):2294-2308
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS
Article: MOLECULAR MEDICINE. 2022;28(1):54
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
Boulouis C; Kammann T; Cuapio A; Parrot T; Gao Y; Mouchtaridi E; Wullimann D; Lange J; Chen P; Akber M; Ballesteros OR; Muvva JR; Smith CIE; Vesterbacka J; Kieri O; Nowak P; Bergman P; Buggert M; Ljunggren H-G; Aleman S; Sandberg JK
Article: BONE MARROW TRANSPLANTATION. 2022;57(5):753-759
Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
Lindahl H; Vonlanthen S; Valentini D; Bjorklund AT; Sundin M; Mielke S; Hauzenberger D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;197(1):82-96
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019
Swan D; Hayden PJ; Eikema D-J; Koster L; Sauer S; Blaise D; Nicholson E; Rabin N; Touzeau C; Byrne J; Huynh A; Cornelissen JJ; Potter V; Forcade E; Parrish C; Gribben J; Chretien M-L; Mielke S; Gedde-Dahl T; Remenyi P; Tsirigotis P; Guinon AG; Beksac M; Schonland S; Yakoub-Agha I
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2022;28(3):s56-s57
66 Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
Kamdar M; Solomon SR; Arnason JE; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri FJ; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS
Article: BONE MARROW TRANSPLANTATION. 2022;57(3):423-430
Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
Bethge WA; Eyrich M; Mielke S; Meisel R; Niederwieser D; Schlegel PG; Schulz A; Greil J; Bunjes D; Brecht A; Kuball J; Schumm M; Vucinic V; Wiesneth M; Bonig H; Westinga K; Biedermann S; Holtkamp S; Karitzky S; Malchow M; Siewert C; Handgretinger R; Lang P
Article: ANNALS OF ONCOLOGY. 2022;33(3):259-275
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Hayden PJ; Roddie C; Bader P; Basak GW; Bonig H; Bonini C; Chabannon C; Ciceri F; Corbacioglu S; Ellard R; Sanchez-Guijo F; Jaeger U; Hildebrandt M; Hudecek M; Kersten MJ; Koehl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Rees J; Rioufol C; Saccardi R; Snowden JA; Styczynski J; Subklewe M; Thieblemont C; Topp M; Ispizua AU; Chen D; Vrhovac R; Gribben JG; Kroeger N; Einsele H; Yakoub-Agha I
Article: MED. 2022;3(2):137-153.e3
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
Healy K; Pin E; Chen P; Soderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Osterborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Lore K; Hellstrom C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Chen MS
Article: MOLECULAR MEDICINE. 2022;28(1):20
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Potti AP; Ballesteros OR; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; Osterborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Lore K; Sobkowiak MJ; Gabarrini G; Healy K; Chen MS; Alici E; Bjorkstrom NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren H-G
Journal article: HEMASPHERE. 2022;6(11)
CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Salmenniemi U; Mielke S; Chevallier P; Therese Rubio M; Balsat M; Pioltelli P; Menard A-L; Socie G; Huynh A; Schaap N; Bermudez Rodriguez A; Cornelissen JJ; Yakoub-Agha I; Aljurf M; Giebel S; Brissot E; Peric Z; Nagler A; Mohty M
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:954716
T cell receptor excision circles are potential predictors of survival in adult allogeneic hematopoietic stem cell transplantation recipients with acute myeloid leukemia
Soderstrom A; Vonlanthen S; Jonsson-Videsater K; Mielke S; Lindahl H; Torlen J; Uhlin M
Article: EBIOMEDICINE. 2021;74:103705
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Soderdahl G; Osterborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgstrom E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Lore K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S
Journal article: BLOOD. 2021;138(Supplement 1):91
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study
Kamdar M; Solomon SR; Arnason JE; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers PGNJ; Hernandez-Ilizaliturri FJ; Izutsu K; Morschhauser F; Lunning MA; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS
Article: THE LANCET ONCOLOGY. 2021;22(10):1403-1415
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu J-M; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
Article: LEUKEMIA. 2021;35(10):2885-2894
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Ljungman P; de la Camara R; Mikulska M; Tridello G; Aguado B; Al Zahrani M; Apperley J; Berceanu A; Bofarull RM; Calbacho M; Ciceri F; Lopez-Corral L; Crippa C; Fox ML; Grassi A; Jimenez M-J; Demir SK; Kwon M; Llamas CV; Lorenzo JLL; Mielke S; Orchard K; Porras RP; Vallisa D; Xhaard A; Knelange NS; Cedillo A; Kroger N; Pinana JL; Styczynski J
Article: JOURNAL OF CLINICAL INVESTIGATION. 2021;131(14):142116
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
Shaim H; Shanley M; Basar R; Daher M; Gumin J; Zamler DB; Uprety N; Wang F; Huang Y; Gabrusiewicz K; Miao Q; Dou J; Alsuliman A; Kerbauy LN; Acharya S; Mohanty V; Mendt M; Li S; Lu J; Wei J; Fowlkes NW; Gokdemir E; Ensley EL; Kaplan M; Kassab C; Li L; Ozcan G; Banerjee PP; Shen Y; Gilbert AL; Jones CM; Bdiwi M; Nunez-Cortes AK; Liu E; Yu J; Imahashi N; Muniz-Feliciano L; Li Y; Hu J; Draetta G; Marin D; Yu D; Mielke S; Eyrich M; Champlin RE; Chen K; Lang FF; Shpall EJ; Heimberger AB; Rezvani K
Article: BONE MARROW TRANSPLANTATION. 2021;56(5):1171-1179
Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study
Styczynski J; Tridello G; Xhaard A; Medinger M; Mielke S; Taskinen M; Blijlevens N; Rodriguez MAB; Solano C; Nikolousis E; Biffi A; Groll AH; Junghanss C; Tsirigotis P; Lioure B; Sramek J; Holler E; Galaverna F; Fagioli F; Knelange N; Wendel L; Gil L; de la Camara R; Mikulska M; Ljungman P
Article: ANNALS OF HEMATOLOGY. 2021;100(3):779-787
Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis
Wertheimer T; Dohse M; Afram G; Weber D; Heidenreich M; Holler B; Kattner A-S; Neubauer A; Mielke S; Ljungman P; Holler E; Herr W; Edinger M; Martinez AP; Fante M; Wolff D
Article: BONE MARROW TRANSPLANTATION. 2021;56(3):622-634
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia
Bazarbachi A; Labopin M; Blaise D; Forcade E; Socie G; Berceanu A; Angelucci E; Bulabois CE; Kroeger N; Rambaldi A; Ceballos P; Mielke S; El Cheikh J; Yakoub-Agha I; Savani B; Spyridonidis A; Nagler A; Mohty M
Article: DIAGNOSTICS. 2021;11(2):312
Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation
Wagner-Drouet E; Teschner D; Wolschke C; Schaefer-Eckart K; Gaertner J; Mielke S; Schreder M; Kobbe G; Hilgendorf I; Klein S; Verbeek M; Ditschkowski M; Koch M; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Wolff D
Article: HAEMATOLOGICA. 2021;106(2):363-374
Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation
Wagner-Drouet E; Teschner D; Wolschke C; Janson D; Schaefer-Eckart K; Gaertner J; Mielke S; Schreder M; Kobbe G; Kondakci M; Hilgendorf I; von Lilienfeld-Toal M; Klein S; Heidenreich D; Kreil S; Verbeek M; Grass S; Ditschkowski M; Gromke T; Koch M; Lindemann M; Huenig T; Schmidt T; Rascle A; Guldan H; Barabas S; Deml L; Wagner R; Wolff D
Article: BONE MARROW TRANSPLANTATION. 2021;56(1):20-29
The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study
Nagler A; Dholaria B; Labopin M; Bruno B; Rambaldi A; Pioltelli P; La Nasa G; Socie G; Mielke S; Ruggeri M; Saccardi R; Franke G-N; Finke J; Savani BN; Ruggeri A; Mohty M
Journal article: BLOOD. 2020;136:5-6
Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B
Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Olsson D; Ejerblad E; Kittang AO; Olesen G; Werlenius O; Bjorklund AT; Lorentz F; Rasmussen BEH; Cammenga J; Weber D; Dimitriou M; Kytola S; Walldin G; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Friis LS; Dybedal I; Lindberg EH
Journal article: BLOOD. 2020;136(Supplement 1):32-33
COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
Ljungman P; De La Camara R; Mikulska M; Tridello G; Aguado B; Beguin Y; Bufarull RM; Ciceri F; Corral LL; Crippa C; Deeren D; Duarte RF; Fox ML; Grassi A; Jimenez M-J; Koculu S; Kwon M; Llamas JCV; Lorenzo JLL; Mielke S; Jiménez JL; Morales ZM; Orchard KH; Porras RP; Potter V; Suárez-Lledó M; Schaap N; Simand C; Sisinni L; Snowden JA; Vallisa D; Yonalhindilerden I; Xhaard A; Knelange NS; Cedillo A; Kröger N; Sanchez JLP; Styczynski J
Article: BLOOD ADVANCES. 2020;4(14):3357-3367
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells
Basar R; Daher M; Uprety N; Gokdemir E; Alsuliman A; Ensley E; Ozcan G; Mendt M; Sanabria MH; Kerbauy LN; Cortes AKN; Li L; Banerjee PP; Muniz-Feliciano L; Acharya S; Fowlkes NW; Lu J; Li S; Mielke S; Kaplan M; Nandivada V; Bdaiwi M; Kontoyiannis AD; Li Y; Liu E; Ang S; Marin D; Brunetti L; Gundry MC; Turk R; Schubert MS; Rettig GR; McNeill MS; Kurgan G; Behlke MA; Champlin R; Shpall EJ; Rezvani K
Article: JOURNAL OF HEMATOLOGY AND ONCOLOGY. 2020;13(1):87
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
Article: LEUKEMIA. 2020;34(7):1907-1923
ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia
Roy DC; Walker I; Maertens J; Lewalle P; Olavarria E; Selleslag D; Lachance S; Buyse M; Wang K; Rovers J; Santi I; Bonig H; Sandler A; Velthuis J; Mielke S
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2020;64(4):e02467-e02419
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
Maertens J; Logan AC; Jang J; Long G; Tang J-L; Hwang WYK; Koh LP; Chemaly R; Gerbitz A; Winkler J; Yeh S-P; Hiemenz J; Christoph S; Lee D-G; Wang P-N; Holler E; Mielke S; Akard L; Yeo A; Ramachandra S; Smith K; Pertel P; Segal F
Article: BLOOD ADVANCES. 2020;4(4):629-637
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
Maziarz RT; Waller EK; Jaeger U; Fleury I; McGuirk J; Holte H; Jaglowski S; Schuster SJ; Bishop MR; Westin JR; Mielke S; Teshima T; Bachanova V; Foley SR; Borchmann P; Salles GA; Zhang J; Tiwari R; Pacaud LB; Ma Q; Tam CS
Article: TRANSPLANT INFECTIOUS DISEASE. 2020;22(1):e13224
Excretion of Ascaris lumbricoides following reduced-intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole
Luber V; Lutz M; Abele-Horn M; Einsele H; Grigoleit GU; Mielke S
Article: HAEMATOLOGICA. 2020;105(1):47-58
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
Dholaria B; Savani BN; Labopin M; Luznik L; Ruggeri A; Mielke S; Al Malki MM; Kongtim P; Fuchs E; Huang X-J; Locatelli F; Aversa F; Castagna L; Bacigalupo A; Martelli M; Blaise D; Ben Soussan P; Arnault Y; Handgretinger R; Roy D-C; O'Donnell P; Bashey A; Solomon S; Romee R; Lewalle P; Gayoso J; Maschan M; Lazarus HM; Ballen K; Giebel S; Baron F; Ciceri F; Esteve J; Gorin N-C; Spyridonidis A; Schmid C; Ciurea SO; Nagler A; Mohty M
Article: LEUKEMIA. 2020;34(1):283-292
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT
Shem-Tov N; Peczynski C; Labopin M; Itala-Remes M; Blaise D; Labussiere-Wallet H; Socie G; Kroeger N; Mielke S; Afanasyev B; Chevallier P; Tischer J; Helbig G; Jindra P; Peric Z; Giebel S; Mohty M; Nagler A
Article: ALTEX. 2020;37(3):429-440
Inflammation-Induced Tissue Damage Mimicking GvHD in Human Skin Models as Test Platform for Immunotherapeutics
Wallstabe J; Bussemer L; Groeber-Becker F; Freund L; Alb M; Dragan M; Waaga-Gasser AM; Jakubietz R; Kneitz H; Rosenwald A; Rebhan S; Walles H; Mielke S
Article: HAEMATOLOGICA. 2020;105(2):297-316
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Yakoub-Agha I; Chabannon C; Bader P; Basak GW; Bonig H; Ciceri F; Corbacioglu S; Duarte RF; Einsele H; Hudecek M; Kersten MJ; Koehl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Robinson S; Saccardi R; Sanchez-Guijo F; Snowden JA; Srour M; Styczynski J; Urbano-Ispizua A; Hayden PJ; Kroeger N
Article: THE LANCET HAEMATOLOGY. 2020;7(1):e28-e39
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Remenyi P; Wagner-Drouet E-M; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stoelzel F; Schetelig J; Junghanss C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Mico MC; Niederwieser D; Franke G-N; Hilgendorf I; Winkelmann NR; Russo D; Socie G; de Latour RP; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Article: BLOOD ADVANCES. 2019;3(23):4034-4042
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
Srinagesh HK; Ozbek U; Kapoor U; Ayuk F; Aziz M; Ben-David K; Choe HK; DeFilipp Z; Etra A; Grupp SA; Hartwell MJ; Hexner EO; Hogan WJ; Karol AB; Kasikis S; Kitko CL; Kowalyk S; Lin J-Y; Major-Monfried H; Mielke S; Merli P; Morales G; Ordemann R; Pulsipher MA; Qayed M; Reddy P; Reshef R; Roesler W; Sandhu KS; Schechter T; Shah J; Sigel K; Weber D; Woelfl M; Wudhikarn K; Young R; Levine JE; Ferrara JLM
Journal article: BLOOD. 2019;134:3338
Impact of Donor-Derived CD34+Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT
Czerw T; Malpassuti V; Iacobelli S; Koster L; Kroeger N; Robin M; Maertens J; Chevallier P; Mielke S; Poire X; Snowden JA; Petersen EJ; Malladi R; Blaise D; Remenyi P; Gandemer V; Cammenga J; Rubio MT; Maury S; Deconinck E; Finnegan D; Hayden P; Boluda JCH; McLornan DP; Yakoub-Agha I
Journal article: BLOOD. 2019;134(Supplement_1):592
Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors
Roy DC; Walker I; Maertens JA; Lewalle P; Olavarria E; Beguin Y; Selleslag D; Wagner EM; Bönig H; Bos G; Mielke S
Journal article: BLOOD. 2019;134(Supplement_1):242
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
Bachanova V; Tam CS; Borchmann P; Jaeger U; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Andreadis C; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Salles G; Schuster SJ; Maziarz RT; Van Besien K; Izutsu K; Kersten MJ; Magenau JM; Wagner-Johnston ND; Kato K; Corradini P; Chu J; Gershgorin I; Choquette T; Pacaud LB; Jeschke M
Journal article: BLOOD. 2019;134(Supplement_1):4103
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
Westin JR; Tam CS; Borchmann P; Jaeger U; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Andreadis C; Foley SR; Fleury I; Ho PJ; Mielke S; Teshima T; Schuster SJ; Bachanova V; Maziarz RT; Van Besien K; Izutsu K; Kersten MJ; Magenau JM; Wagner-Johnston ND; Kato K; Corradini P; Han X; Tiwari R; Agoulnik S; Eldjerou LK; Pacaud LB; Salles GA
Journal article: BLOOD. 2019;134(Supplement_1):2883
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
Andreadis C; Tam CS; Borchmann P; Jaeger U; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Salles GA; Schuster SJ; Bachanova V; Maziarz RT; Van Besien K; Izutsu K; Magenau JM; Wagner-Johnston ND; Kato K; Corradini P; Tiwari R; Awasthi R; Lawniczek T; Eldjerou LK; Kersten MJ
Article: LEUKEMIA. 2019;33(11):2710-2719
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
Knop S; Engelhardt M; Liebisch P; Meisner C; Holler E; Metzner B; Peest D; Kaufmann M; Bunjes D; Straka C; Fischer T; Sezer O; Hentrich M; Ostermann H; Bassermann F; Hess G; Hertenstein B; Freund M; Kropff M; Schmidt CA; Wolf H-H; Jung W; Frickhofen N; Mielke S; Bargou RC; Maschmeyer G; Svaldi M; Langer CH; Gramatzki M; Hebart H; Kanz L; Einsele H; Sezer O; Doerken B; Gerecke C; Fuhrmann S; Ludwig WD; Hertenstein B; Bormann M; Meyer R; Naumann R; Platzbecker U; Roellig C; Roesler W; von Metzler I; Martin H; Engelhardt M; Finke J; Truemper L; Jung W; Schmidt CA; Doelken G; Wolf HH; Mueller L; Ligeti K; Kroeger N; Schilling G; Duerk H; Peest D; Ganser A; Pfreundschuh M; Sayer H; von Lilienfeld-Toal M; Muegge LO; Bentz M; Gramatzki M; Brueggemann M; Fischer T; Wolleschak D; Hess G; Kropff M; Reusch J; Straka C; Ostermann H; Franke D; Peschel C; Dechow T; Bassermann F; Hentrich M; Wandt H; Schaefer-Eckart K; Metzner B; Maschmeyer G; Holler E; Hart C; Reichle A; Freund M; Boettcher S; Kahl C; Mergenthaler HG; Aulitzky W; Kaufmann M; Greiner J; Heidemann E; Kanz L; Hebart H; Liebisch P; Bunjes D; Langer C; Frickhofen N; Einsele H; Knop S; Mielke S; Bargou RC; Svaldi M
Journal article: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19:s251-s252
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Bachanova V; Westin J; Tam C; Borchmann P; Jaeger U; McGuirk J; Holte H; Waller E; Jaglowski S; Bishop M; Andreadis C; Foley RS; Fleury I; Teshima T; Mielke S; Salles G; Ho PJ; Izutsu K; Maziarz R; Van Besien K; Kersten MJ; Wagner-Johnston N; Kato K; Corradini P; Han X; Agoulnik S; Chu J; Eldjerou L; Pacaud L; Schuster S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2019;186(5):754-766
Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis
Roy DC; Lachance S; Cohen S; Delisle J-S; Kiss T; Sauvageau G; Busque L; Ahmad I; Bernard L; Bambace N; Boumedine RS; Guertin M-C; Rezvani K; Mielke S; Perreault C; Roy J
Article: ANNALS OF HEMATOLOGY. 2019;98(8):1867-1875
Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients
Lamby P; Wolff D; Mielke S; Grigoleit GU; Ljungman P; Hilgendorf I; Holler E; Holler B; Weber D; Herr W; Schiltz D; Klein S; Graf S; Bjornhagen-Safwenberg V; Dolderer J; Prantl L
Journal article: HEMASPHERE. 2019;3(S1):338
PF767 PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ONE OR TWO DOSES OF DONOR LYMPHOCYTES DEPLETED OF HOST ALLOREACTIVE T‐CELLS (ATIR101) FOLLOWING T‐CELL‐DEPLETED HAPLOIDENTICAL HSCT
Olavarria E; Lewalle P; Beguin Y; Wagner E; Sandler A; Mielke S; Roy D
Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):505-507
INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL
Jaeger U; Tam C; Borchmann P; McGuirk J; Holte H; Waller E; Jaglowski S; Andreadis C; Foley SR; Fleury I; Westin J; Teshima T; Mielke S; Salles G; Ho PJ; Izutsu K; Schuster S; Bachanova V; Maziarz R; Van Besien K; Kersten MJ; Wagner‐Johnston N; Kato K; Corradini P; Tiwari R; Forcina A; Pacaud L; Bishop M
Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):308-310
CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS
Bachanova V; Westin J; Tam C; Borchmann P; Jaeger U; McGuirk J; Holte H; Waller E; Jaglowski S; Bishop M; Andreadis C; Foley SR; Fleury I; Teshima T; Mielke S; Salles G; Ho PJ; Izutsu K; Maziarz R; Van Besien K; Kersten MJ; Wagner‐Johnston N; Kato K; Corradini P; Han X; Agoulnik S; Chu J; Eldjerou L; Pacaud L; Schuster S
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(3):s53-s54
Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality
Etra A; Gergoudis S; Morales G; Kowalyk S; Lin J-Y; Shah J; Kapoor U; Aziz M; Pawarode A; Ayuk F; Holler E; Choe H; Chen Y-B; Rösler W; Qayed M; Hogan WJ; Wolfl M; Hexner EO; Merli P; Kitko CL; Al Malki MM; Reshef R; Wudhikarn K; Ordemann R; Pulsipher MA; Mielke S; Schechter T; Ozbek U; Ferrara J; Levine JE
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2019;380(1):45-56
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jaeger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJP; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak O; Salles G; Maziarz RT
Journal article: BLOOD. 2018;132(Supplement 1):604
Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning
Lang P; Handgretinger R; Meisel R; Mielke S; Niederwieser D; Schlegel PG; Greil J; Schulz A; Bader P; Brecht A; Bunjes D; Kuball J; Schumm M; Eyrich MK; Vucinic V; Wiesneth M; Bonig H; Westinga K; Karitzky S; Holtkamp S; Malchow M; Siewert C; Biedermann S; Bethge W
Journal article: OPEN FORUM INFECTIOUS DISEASES. 2018;5(suppl_1):s491-s492
1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients
Banas B; Steubl D; Renders L; Chittka D; Banas M; Wekerle T; Koch M; Witzke O; Lindemann M; Muehlfeld A; Sommerer C; Habicht A; Hugo C; Huenig T; Mielke S; Schreder M; Wagner E; Teschner D; Klein S; Heidenreich D; Kreil S; Schaefer-Eckart K; Gaertner J; Verbeek M; Grass S; Wolschke C; Janson D; Kobbe G; Kondakci M; Ditschkowski M; Gromke T; Hilgendorf I; Von Lilienfeld-Toal M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Kraemer B; Krueger B; Wolff D
Journal article: CYTOTHERAPY. 2018;20(5):s10-s11
10 Phase II study of haploidentical stem cell transplantation using ex vivo photodepletion of donor lymphocyte infusions to eliminate anti-host reactivity results in low relapse rates and high survival rates: Final 2 year follow-up
Roy D; Walker I; Maertens J; Lewalle P; Olavarria E; Selleslag D; Lachance S; Bönig H; Mielke S
Article: ANNALS OF HEMATOLOGY. 2017;96(9):1463-1470
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase
Jawhar M; Naumann N; Schwaab J; Baurmann H; Casper J; Tu-Anh D; Dietze L; Doehner K; Haenel A; Lathan B; Link H; Lotfi S; Maywald O; Mielke S; Mueller L; Platzbecker U; Pruemmer O; Thomssen H; Toepelt K; Panse J; Vieler T; Hofmann W-K; Haferlach T; Haferlach C; Fabarius A; Hochhaus A; Cross NCP; Reiter A; Metzgeroth G
Journal article: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2017;17:s373-s374
Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis
Schuster S; Bishop MR; Tam C; Waller EK; Borchmann P; McGuirk J; Jäger U; Jaglowski S; Andreadis C; Westin J; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Anak O; Pacaud L; Awasthi R; Tai F; Salles G; Maziarz RT
Article: JOURNAL OF HEMATOLOGY AND ONCOLOGY. 2017;10(1):130
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb H-J; Ganser A; Schaefer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau I-W; Kroeger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
Journal article: HEMATOLOGICAL ONCOLOGY. 2017;35(S2):27
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS
Schuster SJ; Bishop MR; Tam C; Waller EK; Borchmann P; Mcguirk J; Jäger U; Jaglowski S; Andreadis C; Westin J; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Holte H; Anak O; Pacaud L; Awasthi R; Tai F; Salles G; Maziarz R
Journal article: CYTOTHERAPY. 2017;19(5):e2-e3
LB01 Add back of selectively depleted alloreactive T-cells retaining the full immune repertoire of mature T-cells improves event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT
Boenig HB; Velthuis J; Walker I; Maertens J; Lewalle P; Olavarria E; Selleslag D; Ruediger M; Hoorn MV; Gerez L; Rovers J; Mielke S; Roy DC
Article: HAEMATOLOGICA. 2017;102(4):e160-e162
Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Article: JCI INSIGHT. 2017;2(3):e89798
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell MJ; Ozbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wolfl M; Mielke S; Pawarode A; Chen Y-B; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kroeger N; Locatelli F; Morales G; Nakamura R; Reshef R; Roesler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JLM
Journal article: BLOOD. 2016;128(22):4512
Boost of Immune Responses Against NY-ESO-1 Following Local Radiation Therapy in Patients with Multiple Myeloma: A Potential Contribution to Tumor Immunosurveillance
Alb M; Tamihardja J; Klinker E; Schreder M; Knop S; Einsele H; Hünig T; Rosenwald A; Flentje M; Mielke S
Journal article: BLOOD. 2016;128(22):1226
Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL
Roy D-C; Lachance S; Roy J; Walker I; Maertens J; Delisle J-S; Foley SR; Lewalle P; Olavarria E; Selleslag D; Rüdiger M; Velthuis J; Gerez L; Rovers J; Bonig H; Mielke S
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(11):1988-1996
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features
Rasche L; Roellig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Ruecker V; Schreder M; Schetelig J; Bornhaeuser M; Einsele H; Thiede C; Knop S
Article: BIOTECHNOLOGY JOURNAL. 2016;11(10):1352-1361
Interactions of donor sources and media influence the histo-morphological quality of full-thickness skin models
Lange J; Weil F; Riegler C; Groeber F; Rebhan S; Kurdyn S; Alb M; Kneitz H; Gelbrich G; Walles H; Mielke S
Article: ONKOLOGE. 2016;22(7):488-492
Suicidal ideation in the clinical context of hematopoietic stem cell transplantation. A systematic review
Hefner J; Mielke S; Csef H
Journal article: CYTOTHERAPY. 2016;18(6):s15
26 Phase II Clinical Trial of Allodepleted T Cell Immunotherapy (ATIR101) Post-Transplant Results in Decreased Transplant-Related Mortality and Improved Survival in Acute Leukemia Patients Undergoing T-Depleted Haploidentical Stem Cell Transplantation
Roy D; Lachance S; Roy J; Walker I; Maertens J; Cohen S; Foley R; Lewalle P; Olavarría E; Selleslag D; Ruediger M; Velthuis J; Reitsma K; Gerez L; Rovers J; Bönig H; Mielke S
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(1):4-10
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Harris AC; Young R; Devine S; Hogan WJ; Ayuk F; Bunworasate U; Chanswangphuwana C; Efebera YA; Holler E; Litzow M; Ordemann R; Qayed M; Renteria AS; Reshef R; Woelfl M; Chen Y-B; Goldstein S; Jagasia M; Locatelli F; Mielke S; Porter D; Schechter T; Shekhovtsova Z; Ferrara JLM; Levine JE
Article: ALTEX. 2016;33(4):415-422
A First Vascularized Skin Equivalent as an Alternative to Animal Experimentation
Groeber F; Engelhardt L; Lange J; Kurdyn S; Schmid FF; Ruecker C; Mielke S; Walles H; Hansmann J
Journal article: BLOOD. 2015;126(23):4396
Allogeneic SCT in Multiple Myeloma: Limited Predictive Value of Chimerism Analysis for Heralding Relapse/Progression Due to Extramedullary Disease
Rasche L; Röllig C; Mielke S; Grigoleit GU; Schreder M; Danhof S; Bornhäuser M; Einsele H; Thiede C; Knop S
Journal article: BLOOD. 2015;126(23):4391
Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen
Roy D-C; Lachance S; Roy J; Walker I; Maertens J; Cohen S; Foley SR; Lewalle P; Olavarria E; Selleslag D; Rudiger M; Velthuis J; Reitsma K; Gerez L; Rovers J; Bonig H; Mielke S
Journal article: BLOOD. 2015;126(23):196
Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT
Brissot E; Labopin M; Stelljes M; Ehninger G; Stuhler G; Finke J; Kolb HJ; Ganser A; Schaefer-Eckart K; Kroeger N; Bunjes D; Mielke S; Bethge W; Tabrizi R; Peter K; Blau IW; Glass B; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Nagler A; Mohty M
Journal article: BLOOD. 2015;126(23):3154
Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report
Harris AC; Young R; Devine SM; Hogan WJ; Ayuk F; Bunworasate U; Chanswangphuwana C; Efebera YA; Holler E; Litzow MR; Ordemann R; Qayed M; Renteria AS; Reshef R; Wölfl M; Chen Y-B; Goldstein S; Jagasia MH; Locatelli F; Mielke S; Porter DL; Schechter T; Shekhovtsova Z; Ferrara JLM; Levine JE
Article: LEUKEMIA AND LYMPHOMA. 2015;56(12):3365-3369
Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant
Loeffler C; Kapp M; Grigoleit G-U; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
Article: LEUKEMIA. 2015;29(10):2062-2068
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na I-K; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Luebbert M; Waesch R; Scheid C; Stoelzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Graeff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kroeger N; Passweg J; Halter J; Socie G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Article: BLOOD. 2015;125(2):261-272
Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy
Lutz M; Worschech A; Alb M; Gahn S; Bernhard L; Schwab M; Obermeier S; Einsele H; Kaemmerer U; Heuschmann P; Klinker E; Otto C; Mielkel S
Journal article: BLOOD. 2014;124(21):314
Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS
Roy D-C; Maertens J; Walker I; Lachance S; Roy J; Foley SR; Lewalle P; Selleslag DLD; De Jong L; Velthuis JHL; Gerez L; Reitsma K; Wagena E; Mielke S
Journal article: BLOOD. 2014;124(21):3831
Men Show Significantly Higher T Lymphocyte Mediated Immune Responses Against H-Y Than Multiparous Women: Results from a Cross-Sectional Analysis in 114 Volunteer Blood Donors and Implications for Immunotherapy
Lutz M; Worschech A; Alb M; Gahn S; Bernhard L; Schwab M; Obermeier S; Einsele H; Kämmerer U; Heuschmann P; Klinker E; Otto C; Mielke S
Article: CLINICAL TRANSPLANTATION. 2014;28(12):1410-1415
Improvement of quality of life in patients with steroid-refractory chronic graft-versushost disease treated with the mTOR inhibitor everolimus
Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
Article: BONE MARROW TRANSPLANTATION. 2014;49(11):1412-1418
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis
Mielke S; Lutz M; Schmidhuber J; Kapp M; Ditz D; Ammer J; Einsele H; Grigoleit GU; Holler E; Wolff D
Article: BLOOD. 2014;124(13):2034-2045
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD
Khoder A; Sarvaria A; Alsuliman A; Chew C; Sekine T; Cooper N; Mielke S; de Lavallade H; Muftuoglu M; Curbelo IF; Liu E; Muraro PA; Alousi A; Stringaris K; Parmar S; Shah N; Shaim H; Yvon E; Molldrem J; Rouce R; Champlin R; McNiece I; Mauri C; Shpall EJ; Rezvani K
Journal article: HAEMATOLOGICA. 2014;99(5):830-835
SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.
Hanssens K; Brenet F; Agopian J; Georgin-Lavialle S; Damaj G; Cabaret L; Chandesris MO; de Sepulveda P; Hermine O; Dubreuil P; Soucie E
Article: HAEMATOLOGICA. 2014;99(5):836-847
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
Journal article: CYTOTHERAPY. 2014;16(4):s27
Immunotherapy with donor lymphocytes depleted of anti-host reactive cells results in safe and efficacious haploidentical HSCT: interim results from a phase II trial in patients with hematologic malignancies
Roy D; Maertens J; Walker I; Foley R; Lewalle P; Selleslag D; Velthuis J; Gerez L; Reitsma K; Wagena E; Roy J; Lachance S; Mielke S
Article: BONE MARROW TRANSPLANTATION. 2014;49(4):581-584
High prevalence of distress in patients after allogeneic hematopoietic SCT: Fear of progression is associated with a younger age
Hefner J; Kapp M; Drebinger K; Dannenmann A; Einsele H; Grigoleit G-U; Faller H; Csef H; Mielke S
Journal article: BLOOD. 2013;122(21):4505
Boost and Loss Of Immune Responses Against Tumor-Associated Antigens In The Course Of Pregnancy As a Model For Immunotherapy
Lutz M; Student M; Alb M; Worschech A; Gahn S; Bernhard L; Schwab M; Einsele H; Kämmerer U; Heuschmann P; Klinker E; Otto C; Mielke S
Article: BONE MARROW TRANSPLANTATION. 2013;48(10):1324-1328
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT
Innes AJ; Beattie R; Sergeant R; Damaj G; Foroni L; Marin D; Kanfer E; Mielke S; Milojkovic D; MacDonald D; Pavlu J; Rahemtulla A; Roberts I; Slade D; Bray E; Goldman J; Apperley J; Szydlo R; Dazzi F; Rezvani K
Article: BLOOD. 2013;122(2):227-238
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
de Lavallade H; Khoder A; Hart M; Sarvaria A; Sekine T; Alsuliman A; Mielke S; Bazeos A; Stringaris K; Ali S; Milojkovic D; Foroni L; Chaidos A; Cooper N; Gabriel I; Apperley J; Belsey S; Flanagan RJ; Goldman J; Shpall EJ; Kelleher P; Marin D; Rezvani K
Journal article: BLOOD. 2012;120(21):4173
Salvage Therapy with Everolimus Reduces the Severity of Treatment-Refractory Chronic Graft-Versus-Host Disease without Impairing Disease Control: A Dual Center Experience
Mielke S; Lutz M; Schmidhuber J; Kapp M; Ammer J; Einsele H; Grigoleit GU; Holler E; Wolff D
Journal article: BLOOD. 2012;120(21):4115
Immune Responses Against the Tumor-Associated Antigens WT1, MUC-1, PRAME and HER2/Neu in 114 Prospectively Screened Healthy Donors: Effects of Gender and Prior Pregnancy and Implications for Immunotherapy
Lutz M; Worschech A; Gahn S; Bernhard L; Schwab M; Einsele H; Kämmerer U; Heuschmann P; Klinker E; Otto C; Mielke S
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(7):1125-1136
Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy
Rezvani K; Yong ASM; Mielke S; Savani BN; Jafarpour B; Eniafe R; Le RQ; Musse L; Boss C; Childs R; Barrett AJ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(12):1855-1861
Selectively T Cell-Depleted Allografts from HLA-Matched Sibling Donors Followed by Low-Dose Posttransplantation Immunosuppression to Improve Transplantation Outcome in Patients with Hematologic Malignancies
Mielke S; McIver ZA; Shenoy A; Fellowes V; Khuu H; Stroncek DF; Leitman SF; Childs R; Battiwalla M; Koklanaris E; Haggerty J; Savani BN; Rezvani K; Barrett AJ
Journal article: BLOOD. 2011;118(21):3020
Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units
Roy D-C; Guerin M; Boumedine RS; Lachance S; Cohen S; Sauvageau G; Kiss T; Busque L; Morin J; Guertin M-C; Velardi A; Rezvani K; Mielke S; Egeler RM; Barrett AJ; Perreault C; Roy J
Article: HAEMATOLOGICA. 2011;96(3):432-440
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8⁺ T cells in myeloid malignancies
Rezvani K; Yong ASM; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(2):s286
Selectively T Cell Depleted Allografts From HLA-Matched Sibling Donors Followed by Low-Dose Post Transplant Immunosuppression to Limit Disease Relapse in Patients With Hematological Malignancies
McIver ZA; Mielke S; Shenoy A; Fellows V; Stroncek D; Leitman S; Childs R; Batiwalla M; Koklanaris EK; Haggerty J; Savani BN; Rezvani K; Barrett AJ
Journal article: BLOOD. 2010;116(21):4705
Selectively T Cell Depleted Allografts From HLA-Matched Sibling Donors Followed by Low-Dose Post Transplant Immunosuppression to Limit Disease Relapse In Patients with Hematological Malignancies
McIver ZA; Mielke S; Shenoy A; Fellows V; Stroncek D; Leitman S; Childs R; Battiwalla M; Koklanaris EK; Haggerty J; Savani BN; Rezvani K; Barrett AJ
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2010;16(2):s300
PR1-Specific T Cell Responses In The First Months Following T-Cell Depleted Allogeneic Stem Cell Transplantation Occur In Both Myeloid And Non-Myeloid Malignancies But Are Only Associated With A GVL Effect In Myeloid Leukemias
Rezvani K; Mielke S; Yong A; Savani BN; Jafarpour B; Eniafe R; Barrett AJ
Journal article: BLOOD. 2009;114(22):515
Allografts Selectively Photodepleted of GvHD Causing T Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve Disease Control After HLA-Matched Sibling Transplantations.
Mielke S; Shenoy A; Rezvani K; Yong ASM; McIver ZA; Fellowes VS; Savani BN; Kurlander R; Khuu H; Boss C; Barrett AJ
Journal article: BLOOD. 2009;114(22):4096
The Response to Repeated Vaccination with PR1 and WT1 Peptides Admixed in Montanide Adjuvant Is Transient and Fails to Induce Sustained Anti-Leukemia Responses in Patients with Myeloid Malignancies.
Rezvani K; Yong ASM; Mielke S; Jafarpour B; Savani BN; Le Q; Eniafe R; Boss C; Kurlander RJ; Barrett AJ
Article: BLOOD. 2009;114(13):2829-2836
Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease
Stuehler C; Mielke S; Chatterjee M; Duell J; Lurati S; Rueckert F; Einsele H; Bargou RC; Topp MS
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 2009;47(7):2328-2331
Life-Threatening Infection Caused by Daptomycin-Resistant Corynebacterium jeikeium in a Neutropenic Patient
Schoen C; Unzicker C; Stuhler G; Elias J; Einsele H; Ulrich G; Abele-Horn M; Mielke S
Journal article: JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2009;14(2):69-71
CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study.
CI-PERINOMS Study Group
Article: BLOOD. 2009;113(10):2245-2255
Ex vivo characterization of polyclonal memory CD8⁺ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia
Rezvani K; Yong ASM; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Li Y; Kurlander R; Barrett AJ
Journal article: BLOOD. 2008;112(11):2910
Ex-Vivo Characterization of Polyclonal Memory CD8+ T-Cell Responses to PRAME-Specific Peptides in Patients with Acute Leukemia and Chronic Myeloid Leukemia
Rezvani K; Yong ASM; Tawab A; Jafarpour B; Eniafe R; Mielke S; Savani BN; Keyvanfar K; Yixin L; Kurlander R; Barrett AJ
Journal article: BLOOD. 2008;112(11):1168
Selective Allodepletion by TH9402-Mediated Photosensitization Results in Early Full Donor T Cell Reconstitution in the Absence of High-Grade, Acute GvHD and Is Associated with Favorable Outcome after HLA Matched Sibling SCT for Hematologic Malignancies
Mielke S; Shenoy A; Fellowes VS; Rezvani K; Savani BN; Musse L; Wisch L; Kurlander R; Khuu H; Boss C; Barrett AJ
Article: BLOOD. 2008;111(8):4392-4402
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique
Mielke S; Nunes R; Rezvani K; Fellowes VS; Venne A; Solomon SR; Fan Y; Gostick E; Price DA; Scotto C; Read EJ; Barrett AJ
Article: BLOOD. 2008;111(1):236-242
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Rezvani K; Yong ASM; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
Journal article: BLOOD. 2007;110(11):3279
Successful Translation of a GMP-Based, Clinical Scale Selective Allodepletion Approach for Matched Donor-Recipient Pairs from Bench-to-Bedside.
Mielke S; Nunes R; Rezvani K; Fellowes VS; Venne A; Solomon SR; Fan Y; Scotto C; Read EJ; Barrett AJ
Journal article: BLOOD. 2007;110(11):287
Leukemia-Associated Antigen Specific T-Cell Responses Following Combined PR1 and WT1 Peptide Vaccination in Patients with Myeloid Malignancies.
Rezvani K; Yong ASM; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(10):1216-1223
Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation
Savani BN; Mielke S; Rezvani K; Montero A; Yong AS; Wish L; Superata J; Kurlander R; Singh A; Childs R; Barrett AJ
Article: LEUKEMIA. 2007;21(10):2145-2152
Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
Savani BN; Mielke S; Adams S; Uribe M; Rezvani K; Yong ASM; Zeilah J; Kurlander R; Srinivasan R; Childs R; Hensel N; Barrett AJ
Article: BLOOD. 2007;110(6):1924-1932
Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia
Rezvani K; Yong ASM; Savani BN; Mielke S; Keyvanfar K; Gostick E; Price DA; Douek DC; Barrett AJ
Article: BLOOD. 2007;110(5):1603-1606
Deficient CD4⁺ CD25⁺ FOXP3⁺ T regulatory cells in acquired aplastic anemia
Solomou EE; Rezvani K; Mielke S; Malide D; Keyvanfar K; Visconte V; Kajigaya S; Barrett AJ; Young NS
Article: BLOOD. 2007;110(2):770-775
High PR3 or ELA2 expression by CD34⁺ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
Yong ASM; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett AJ
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):121
333: Cytotoxic T lymphocyte responses to PR1 peptide in CML patients inversely correlate with proteinase 3 and elastase expression but donor PR1-responses determine molecular remission and disease eradication after stem cell transplantation
Yong ASM; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett J
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):117-118
323: Day 30 post-transplant absolute lymphocyte and natural killer cell count strongly predict outcome after allogeneic stem cell transplantation for hematological malignancy
Savani BN; Mielke S; Rezvani K; Yong A; Shenoy A; Read EJ; Hensel N; Childs R; Barrett AJ
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):114
314: Selective depletion of alloreacting T cells by TH9402-based photodepletion as a translational strategy for GVHD control in HLA-mismatched and matched donor-recipient pairs
Mielke S; Nunes R; Rezvani K; Fellowes VS; Fan Y; Scotto C; Solomon SP; Read EJ; Barrett AJ
Article: ONKOLOGIE. 2007;30(1-2):49-52
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation
Mielke S; Potthoff K; Feuerhake F; Bley TA; Windfuhr M; Bertz H; Finke J
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2007;81(1):76-82
Variants in the SLCO1B3 gene:: Interethnic distribution and association with paclitaxel pharmacokinetics
Smith NF; Marsh S; Scott-Horton TJ; Hamada A; Mielke S; Mross K; Figg WD; Verweij J; McLeod HL; Sparreboom A
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(12):1318-1325
T cell depleted peripheral blood stem cell allotransplantation with T cell add back for patients with hematological malignancies: Effect of chronic GVHD on outcome
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(12):1261-1269
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation
Savani BN; Montero A; Srinivasan R; Singh A; Shenoy A; Mielke S; Rezvani K; Karimpour S; Childs R; Barrett AJ
Journal article: BLOOD. 2006;108(11):721
High Efficiency Clinical Scale Selective Depletion of Alloreacting T Cells Using Expanded T Lymphocytes as Antigen-Presenting Cells and a TH9402-Based Photodepletion Technique in HLA-Mismatched and Matched Donor-Recipient Pairs.
Mielke S; Nunes R; Rezvani K; Fellowes VS; Fan Y; Solomon SR; Scotto C; Read EJ; Barrett AJ
Journal article: BLOOD. 2006;108(11):5195
PR1-Specific T Cell Responses in the First Months Following T-Cell Depleted Allogeneic Stem Cell Transplantation Occur in Both Myeloid and Non-Myeloid Malignancies but Are Only Associated with a GVL Effect in Myeloid Leukemias.
Rezvani K; Agnes Y; Eniafe RB; Mielke S; Savani BN; Price DA; Gostick E; Douek DC; Goldman JM; Barrett AJ
Journal article: BLOOD. 2006;108(11):3697
Cytotoxic T Lymphocyte Responses to PR1 Peptide in Chronic Myeloid Leukemia Patients Inversely Correlate with Proteinase 3 and Elastase Expression but Donor PR1 Responses Determine Survival after Stem Cell Transplantation.
Yong ASM; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett AJ
Journal article: BLOOD. 2006;108(11):3679
WT1-Specific CD8+ T Lymphocytes May Participate in the Elimination of Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation.
Rezvani K; Yong A; Mielke S; Savani BN; Price DA; Gostick E; Douek DC; Barrett AJ
Journal article: BLOOD. 2006;108(11):308
Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts Preserves a CD25− CD4+foxp3+ Fraction of T Cells and Thereby Provides a Source for Efficient Reconstitution of Regulatory T Cells and Additional GVHD Control.
Mielke S; Rezvani K; Solomon SR; Savani BN; Nunes R; Yong A; Schindler J; Read EJ; Vitetta ES; Barrett AJ
Journal article: BLOOD. 2006;108(11):2993
Total Lymphocyte and Natural Killer (NK) Cell Count Day 30 Post-Transplant Strongly Predict Transplant Outcome after T Cell Depleted Allogeneic Stem Cell Transplantation.
Savani BN; Mielke S; Rezvani K; Yong A; Hensel N; Read EJ; Childs R; Barrett AJ
Journal article: BLOOD. 2006;108(11):2248
FOXP3-Positive Regulatory T-Cells in Acquired Aplastic Anemia.
Solomou EE; Rezvani K; Mielke S; Malide D; Visconte V; Keyvanfar K; Bruno TC; Barrett AJ; Young NS
Article: EUROPEAN JOURNAL OF CANCER. 2006;42(17):2893-2896
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Sissung TM; Mross K; Steinberg SM; Behringer D; Figg WD; Sparreboom A; Mielke S
Article: BLOOD. 2006;108(4):1291-1297
High donor FOXP3-positive regulatory T-cell (T_reg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT
Rezvani K; Mielke S; Ahmadzadeh M; Kilical Y; Savani BN; Zeilah J; Keyvanfar K; Montero A; Hensel N; Kurlander R; Barrett AJ
Article: BLOOD. 2006;107(4):1688-1695
Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia
Savani BN; Rezvani K; Mielke S; Montero A; Kurlander R; Carter CS; Leitman S; Read EJ; Childs R; Barrett AJ
Journal article: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):103
A novel strategy for selective depletion of host-reactive donor lymphocytes by photodepletion is efficient at clinical scale conditions and preserves foxp3+ regulatory T cells
Mielke S; Rezvani K; Fellowes V; Venne A; Solomon SR; Fan Y; Hensel N; Carter CS; Read EJ; Barrett AJ
Article: CLINICAL CANCER RESEARCH. 2005;11(24):8799-8807
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: Identification, quantification, and characterization
Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li JM; Mielke S; Douek DC; Barrett AJ
Journal article: BLOOD. 2005;106(11):595
Reconstitution of Regulatory T Cells after Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts and Association with Acute Graft-Versus-Host-Disease.
Mielke S; Rezvani K; Solomon SR; Kilical Y; Savani BN; Wish L; Carter CS; Schindler J; Hensel N; Kurlander R; Read EJ; Vitetta ES; Barrett AJ
Journal article: BLOOD. 2005;106(11):2764
Identification of Novel MHC Class I and Class II Epitopes of WT1 Using a Peptide Library Screen.
Rezvani K; Mielke S; Kilical Y; Grube M; Fujiwara H; Sconocchia G; Lee J; El-Ouriaghi F; Hensel N; Barrett AJ
Journal article: BLOOD. 2005;106(11):2384
Robust Expansion of Cytomegalovirus (CMV) Antigen-Specific CD4+ and CD8+ T Cells Using Gene-Modified Activated T Cells as Antigen Presenting Cells.
Melenhorst JJ; Solomon SR; Mielke S; Hensel NF; Barrett AJ
Journal article: BLOOD. 2005;106(11):1416
Inverse Correlation of Early Regulatory T Cell Reconstitution Post-Transplant and Acute and Chronic Graft-Versus-Host-Disease.
Rezvani K; Mielke S; Kilical Y; Savani B; Keyvanfar K; Hensel N; Kurlander R; Barrett AJ
Journal article: BLOOD. 2005;106(11):140
T-Cell Depleted PBSCT Mitigates Acute GVHD, but Preserves Protective Chronic GVHD. Long Term Follow up of 138 Patients.
Montero A; Savani BN; Mielke S; Solomon SR; Childs R; Barrett AJ
Journal article: BLOOD. 2005;106(11):1405
Transplant Outcome in Acute Myeloid but Not Acute Lymphocytic Leukemia Following T Cell Depleted Allogeneic Stem Cell Transplantation May Be Favorably Influenced by Early Recovery of NK Cells.
Savani BN; Montero A; Mielke S; Rezvani K; Shenoy A; Childs R; Barrett AJ
Article: CLINICAL CANCER RESEARCH. 2005;11(22):8097-8104
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Article: ANTICANCER RESEARCH. 2005;25(6C):4423-4427
Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen
Mielke S; Sparreboom A; Behringer D; Mross K
Article: BLOOD. 2005;106(3):1123-1129
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation
Solomon SR; Mielke S; Savani BN; Montero A; Wisch L; Childs R; Hensel N; Schindler J; Ghetie V; Leitman SF; Mai T; Carter CS; Kurlander R; Read EJ; Vitetta ES; Barrett AJ
Article: CLINICAL CANCER RESEARCH. 2005;11(13):4843-4850
Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Article: CYTOTHERAPY. 2005;7(2):109-115
Selective depletion strategies in allogeneic stem cell transplantation
Mielke S; Solomon SR; Barrett AJ
Journal article: BLOOD. 2004;104(11):426
Selective Depletion of Alloreacting CD25+ Cells from Stem Cell Allografts Can Reduce Acute Graft-Versus-Host Disease Following Matched Related Donor Transplantation.
Solomon SR; Tran T; Carter CS; Hensel N; Wisch L; Mielke S; Read E; Ghetie V; Schindler J; Vitetta E; Barrett J
Article: GEBURTSHILFE UND FRAUENHEILKUNDE. 2004;64(11):1199-1204
Practical aspects in the treatment of metastatic breast cancer with administration of paclitaxel weekly
Jackisch C; Grothey A; Schlotter CM; Mielke S; Wassmann KI; Behringer D; Mross K; Rody A
Article: ANTI-CANCER DRUGS. 2003;14(10):785-792
Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h.
Mielke S; Mross K; Gerds TA; Schmidt A; Wäsch R; Berger DP; Lange W; Behringer D
Article: IN VIVO. 2003;17(5):505-507
Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells
Lohr J; Mielke S; Lübbert M; Behringer D
Journal article: EJC SUPPLEMENTS. 2003;1(5):s164
542 A multicenter, randomized phase III study on neurotoxicity, safety and efficacy of weekly Pacilitaxel infused over 1-h vs. 3-h in patients with advanced solid tumors
Mielke S; Mross K; Gerds TA; Schmidt A; Lange W; Behringer D
Article: ONKOLOGIE. 2002;25(6):503-508
Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics:: Results from a randomized trial
Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(2):574-581
Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions
Gelderblom H
Article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(2):574-581
Comparative pharmacokineties of unbound paclitaxel during 1-and 3-hour infusions
Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
Article: HANDCHIRURGIE MIKROCHIRURGIE PLASTISCHE CHIRURGIE. 1999;31(4):241-245
[Results of therapy after primary conservative management of distal radius fractures in patients over 65 years of age].
Jakob M; Mielke S; Keller H; Metzger U
Article: MEDICAL HYPOTHESES. 1998;50(5):359-362
Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis
Mielke S; Meden H; Kuhn W
Article: GYNECOLOGICAL ENDOCRINOLOGY. 1997;11(4):237-241
In vivo effects of estrogens on c-erbB-2 oncoprotein levels in chorionic villous tissue and maternal serum
Mielke S; Meden H; Marx D; Wuttke W; Kuhn W
Article: ANTICANCER RESEARCH. 1997;17(4B):3125-3127
Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum
Mielke S; Meden H; Raab T; Wuttke W; Kuhn W
Article: ANTICANCER RESEARCH. 1997;17(4B):3075-3077
Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations
Meden H; Mielke S; Marx D; Wuttke W; Kuhn W
Article: JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH. 1997;23(2):213-217
Elevated serum levels of the c-erbB-2 encoded oncoprotein fragment in cases of pure preeclampsia and HELLP syndrome.
Meden H; Mielke S; Wuttke W; Kuhn W
Article: IN VIVO. 1997;11(1):51-54
Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies
Meden H; Mielke S; Schauer A; Kuhn W
Visa fler

Alla övriga publikationer

Letter: BONE MARROW TRANSPLANTATION. 2024;59(11):1631-1634
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT
Novak U; Mooyaart JE; Daskalakis M; Scheid C; Gabellier L; Yakoub-Agha I; Ram R; Forcade E; Lopez-Corral L; Nicholson E; Galli E; Stoelzel F; Bethge W; Wagner-Drouet EM; Hoogenboom JD; Mielke S; Arber C; Simonetta F; Chabannon C; Kuball J; Ruggeri A; Malard F
Corrigendum: NATURE MEDICINE. 2024;30(8):2374
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F; Dahiya S; Palomba ML; Martin Garcia-Sancho A; Reguera Ortega JL; Kuruvilla J; Jäger U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Kumar J; Nastoupil LJ
Review: FUTURE ONCOLOGY. 2024;20(21):1455-1465
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Review: THE LANCET HAEMATOLOGY. 2024;11(2):e147-e159
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Penack O; Marchetti M; Aljurf M; Arat M; Bonifazi F; Duarte RF; Giebel S; Greinix H; Hazenberg M; Kroeger N; Mielke S; Mohty M; Nagler A; Passweg J; Patriarca F; Ruutu T; Schoemans H; Solano C; Vrhovac R; Wolff D; Zeiser R; Sureda A; Peric Z
Conference publication: 2023;:a736
643 A first in human phase I/IIa trial of personalized tumor-trained lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer
Berglund S; Joly A-L; Maitre EL; Day K; Notari L; Carvalho-Queiroz C; Nilsson O; Kaiser A; Kordes M; Yachnin J; Carlsten M; Mielke S; Chabok A; Nikberg M; Tarfy AS; Salmén A; Svensson S; Xie H; Gafvelin G; Grönlund H
Conference publication: LEUKEMIA RESEARCH. 2023;128:107227
COMPARISON OF MRD-MARKERS USING MUTATION-SPECIFIC DDPCR IN BONE MARROWAND PERIPHERAL BLOOD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS
Lindholm C; Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Kittang AO; Werlenius O; Wiggh J; Lorentz F; Rasmussen B; Cammenga J; Weber D; Moen AE; Lundstrom LY; Von Bahr L; Dimitriou M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SE; Ebeling F; Cavelier L; Friis LS; Dybedal I; Hellstrom-Lindberg E
Conference publication: BRITISH JOURNAL OF HAEMATOLOGY. 2023;201:10-11
Lisocabtagene maraleucel in second-line large B-ell lymphoma: Primary analysis of phase 3 TRANSFORM study
Davies A; Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):281-282
EFFICACY OF PTCY-BASED GVHD-PROPHYLAXIS IN ADULTS OLDER THAN 55 WITH MYELOID MALIGNANCIES UNDERGOING ALLO-HCT ACCORDING TO DONOR TYPE: STUDY FROM THE TCWP OF THE EBMT
Queralt Salas M; Peczynski C; Sengeloev H; Blaise D; Gedde-Dahl T; Blau IW; de Latour RP; Schoemans H; Schroeder T; Kroeger N; Burns D; Mielke S; Eder ME; Ciceri F; Robin M; McLornan DP; Boreland W; Moiseev I; Olaf P; Koenecke C; Peric Z
Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):85-86
INFLUENCE OF PRE-EXISTING INVASIVE ASPERGILLOSIS ON ALLO-HSCT OUTCOME IN ACUTE LEUKEMIA PATIENTS: A PROSPECTIVE STUDY OF THE EBMT INFECTIOUS DISEASES WORKING PARTY
Penack O; Tridello G; Salmenniemi U; Martino R; Khanna N; Velardi A; Fagioli F; Richert-Przygonska M; Labussiere-Wallet H; Maertens J; Jubert C; Aljurf M; Pichler H; Krivan G; Alakel N; Popova M; Gabriel M; Calore E; Blau IW; Benedetti F; Itala-Remes M; Blijlevens N; Russo D; Faraci M; Tilly H; Borne PVD; Poire X; Yesilipek A; Gozdzik J; Yegin ZA; Yanez L; Facchini L; Van Gorkom G; Thurner L; Kocak U; Sampol A; Zuckerman T; Bierings M; Mielke S; Ciceri F; Wendel L; Knelange N; Mikulska M; Averbuch D; Styczynski J; de la Camara R; Cesaro S
Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):66-67
GVHD PROPHYLAXIS INCORPORATING METHOTREXATE IN ALLO-HCT FOR CHRONIC MYELOID MALIGNANCIES AND SAML: A RETROSPECTIVE ANALYSIS FROM THE CMWP OF THE EBMT
Luft T; Gras L; Koster L; Kroeger N; Schroeder T; Patzbecker U; Bornhaeuser M; de Latour RP; Stelljes M; Sengeloev H; Ganser A; Blau IW; Dreger P; Yakoub-Agha I; Maertens J; Salmenniemi U; Bethge W; Mielke SM; Kobbe G; Pouli A; de Wreede L; Raj K; Drozd-Sokolowska J; Mc Lornan D; Robin M
Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):58-59
ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY
Bug G; Labopin M; Byrne JL; Mielke S; Orchard K; Burns D; Potter V; Blaise D; Robinson S; Snowden J; Yakoub-Agha I; Clark A; Crawley C; Spyridonidis A; Sanz J; Brissot E; Giebel S; Ciceri F; Mohty M
Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):466-467
ROLE OF HLA EVOLUTIONARY DIVERGENCE IN SINGLE HLAMISMATCHED UNRELATED DONOR HCT FOR MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT ON BEHALF OF THE CTIWP OF THE EBMT
Pagliuca S; Mooyaart JE; Kroeger N; Finke J; Potter V; Dreger P; Hilgendorf I; Bethge W; de latour RP; Rambaldi A; Sengeloev H; Passweg J; Gedde-Dahl T; Burns D; Orchard K; Mielke S; Edinger M; Andreani M; Crivello P; Merli P; Hoogenboom JD; de Wreede LC; Chabannon C; Kuball J; Gurnari C; Fleischhauer K; Ruggeri A; Lenz TL
Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):143-144
ASSOCIATIONS BETWEEN HLA EVOLUTIONARY DIVERGENCE AND OUTCOME OF MATCHED RELATED OR UNRELATED HCT: A STUDY FROM THE EBMT CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY
Crivello P; Mooyaart JE; Kroeger N; de latour RP; Sengeloev H; Yakoub-Agha I; Finke J; Bethge W; Dreger P; Potter V; Burns D; Gedde-Dahl T; Huynh A; Mielke S; Eder M; Bulabois CE; Forcade E; Broers AEC; Salmenniemi U; Hilgendorf I; Choi G; Byrne J; Orchard K; Gandemer V; Deconinck E; Merli P; Andreani M; Pagliuca S; Gurnari C; Hoogenboom JD; de Wreede LC; Lenz T; Chabannon C; Ruggeri A; Fleischhauer K
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2023;46:272-273
Lisocabtagene Maraleucel (Liso-cel) vs Standard of Care (SOC) with Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 TRANSFORM Study
Glass B; Abramson JS; Solomon SR; Arnason JE; Johnston PB; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning MA; Crotta A; Montheard S; Previtali A; Kamdar M
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2023;46:75
Immune Effector Cell-Associated Hematoxicity (ICAHT): Novel Consensus Grading and Management Recommendations on Behalf of EHA and EBMT
Rejeski K; Greco R; Jaeger U; Mielke S; Onida F; Sanchez-Ortega I; Schneidawind D; Schubert M-L; Topp M; Gribben J; Bonini C; Sureda A; Yakoub-Agha I; Subklewe M
Conference publication: JOURNAL OF IMMUNOLOGY. 2023;210(1)
Anamnestic expansion of Omicron-reactive CD8+T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states
Mueller TR; Sekine T; Trubach D; Niessl J; Olofsson A; Gao Y; Cai C; Nowak P; Blennow O; Hansson L; Mielke S; Bergman P; Ljunggren H-G; Karlsson AC; Saini SK; Aleman S; Buggert M
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2023;23:S447-S448
TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)
Nastoupil LJ; Dahiya S; Palomba ML; Martin Garcia-Sancho A; Reguera Ortega JL; Kuruvilla J; Jager U; Cartron G; Izutsu KI; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Morschhauser F
Conference publication: BLOOD. 2022;140:1581-1583
Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
Abramson JS; Solomon SR; Arnason JE; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning MA; Crotta A; Montheard S; Previtali A; Kamdar M
Conference publication: BLOOD. 2022;140:900-902
Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
Luft T; Gras L; Kostner L; Kroeger N; Schroeder T; Platzbecker U; Schetelig J; de Latour RP; Stelljes M; Sengeloev H; Ganser A; Blau IW; Dreger P; Yakoub-Agha I; Maertens J; Salmenniemi U; Bethge W; Mielke S; Kobbe G; Pouli A; de Wreede LC; Raj K; Drozd-Sokolowska J; McLornan DP; Robin M
Letter: BLOOD ADVANCES. 2022;6(16):4816-4820
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Jaeger U; Tam CS; Borchmann P; McGuirk JP; Johansen M; Waller EK; Jaglowski S; Andreadis C; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Salles G; Schuster SJ; He F; Maziarz RT; Mayer S; Makita S; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Goto H; Colicino S; Agarwal A; Lobetti-Bodoni C; Bishop MR
Preprint: RESEARCH SQUARE. 2022
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: A Study from the Acute Leukemia Working Party of the EBMT
Bug G; Labopin M; Niittyvuopio R; Stelljes M; Reinhardt C; Hilgendorf I; Kroeger N; Kaare A; Bethge W; Schaefer-Eckart K; Verbeek M; Mielke S; Carlson K; Bazarbachi A; Spyridonidis A; Savani B; Nagler A; Mohty M
Preprint: RESEARCH SQUARE. 2022
Reversible Streptamer Technology Facilitates the Selection of T Regulatory Cells From Cryopreserved Cord Blood
Duggleby R; Shah DK; Strange KE; Tsang HP; Stemberger C; Germeroth L; Mielke S; Bonig H; Einsele H; Roberts D; Querol S; Madrigal A; Saudemont A; Hernandez D; Danby R
Letter: LEUKEMIA AND LYMPHOMA. 2022;63(3):755-758
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation
Jadersten M; Boriskina K; Lindholm C; Westrom S; Cavelier L; Hellstrom-Lindberg E; Mielke S; Tobiasson M
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2022;45(SUPPL 3):55
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and non-small cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
Ullrich R; Wermke M; Yachnin J; Mielke S; Patel R; Yushak ML; Schoenfeld AJ; Desai J; Altan M; D'angelo SP; Noujaim J; Haanen JBAG; Powers B; Faitg T; Liu W; Patel N; Araujo DM
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2022;45(SUPPL 3):165-166
Phase 3 TRANSFORM study of lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor T cell therapy (Tx), versus standard of care (SOC) of salvage chemotherapy followed by autologous stem cell transplantation (ASCT) as second-line (2L) Tx in patients (pt) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
Glass B; Kamdar M; Solomon S; Arnason J; Johnston PB; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney D; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Abramson J
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2022;45(SUPPL 3):179
ZENYTH-ESO Substudy 1 (GSK3901961), Cohort 1: a first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer
Wermke M; Ullrich R; Yachnin J; Mielke S; Patel R; Yushak ML; Schoenfeld AJ; Desai J; Altan M; D'angelo SP; Noujaim J; Haanen JBAG; Powers B; Faitg T; Liu W; Patel N; Araujo DM
Conference publication: BONE MARROW TRANSPLANTATION. 2022;57(SUPPL 1):163-164
Thiotepa-based reduced-intensity conditioning are a valid alternative to total-body irradiation-based regimens in patients with acute lymphoblastic leukemia: A study of the alwp of the ebmt
Battipaglia G; Labopin M; Mielke S; Ruggeri A; Ozkurt ZN; Bourhis JH; Rabitsch W; Yakoub-Agha I; Grillo G; Sanz J; Arcese W; Novis Y; Fegueux N; Giebel S; Nagler A; Mohty M
Conference publication: BONE MARROW TRANSPLANTATION. 2022;57(SUPPL 1):188-189
Methotrexate or mycophenolate mofetil with cyclosporine and antithymocyte globulin in matched unrelated donor transplantation for acute myeloid leukemia with busulfan-fludarabine reduced-intensity conditioning: An alwp study
Battipaglia G; Galimard J-E; Labopin M; Socie G; Forcade E; Bulabois CE; Schanz U; Fegueux N; Mielke S; Carlson K; Deconinck E; Maertens J; Guillerm G; Turlure P; Gedde-Dahl T; Nagler A; Mohty M
Conference publication: BONE MARROW TRANSPLANTATION. 2022;57(SUPPL 1):19-20
CD34+dose effects on clinical outcomes after fludarabine-busulfan conditioning regimen for acute myeloid leukemia using peripheral blood stem cells-study from the ALWP of EBMT
Brissot E; Galimard J-E; Socie G; Blaise D; Forcade E; Fegueux N; Maertens J; Daguindau E; Bourhis J-H; Bulabois CE; Mielke S; Huynh A; Gedde-Dahl T; Lioure B; Yakoub-Agha I; Griskevicius L; Rubio M-T; Chevallier P; Bay J-O; Byrne J; Turlure P; Chantepie S; Giebel S; Nagler A; Mohty M
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2022;45(SUPPL 2):194
Phase 3 TRANSFORM study of lisocabtagen maraleucel (Liso-Cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, versus standard of care (SOC) as second-line therapy (2L) in patients (pt) with relapsed or refractory large B-cell lymphoma (LBCL)
Glass B; Kamdar M; Solomon SR; Arnason J; Johnston PB; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Abramson JS
Conference publication: BONE MARROW TRANSPLANTATION. 2022;57(SUPPL 1):264
Outcome of post-vaccination covid-19 in hematopoietic stem cell transplant and car t cell treatment recipients; results from an idwp prospective survey
Ljungman P; Mikulska M; Collin M; Gambella M; Mielke S; Sica S; Sengeloev H; Suarez-Lledo M; Yegin ZA; Valerius T; Wilson KM; Zuckerman T; Yonal-Hindilerden I; Ghesquieres H; Knelange N; Tridello G; Averbuch D; Cordonnier C; Cesaro S; De la Camara R
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2022;45(SUPPL 2):159
Detection of T-cell Immune Responses against Cytomegalovirus in seronegative healthy Blood Donors: a potential Source for adoptive Immune Transfer?
Lutz M; Guennoun A; Alb M; Weissbrich B; Klinker E; Bussemer L; Einsele H; Ljungman P; Otto C; Mielke S
Letter: LEUKEMIA. 2021;35(12):3585-3588
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Spanjaart AM; Ljungman P; de La Camara R; Tridello G; Ortiz-Maldonado V; Urbano-Ispizua A; Barba P; Kwon M; Caballero D; Sesques P; Bachy E; Di Blasi R; Thieblemont C; Calkoen F; Mutsaers P; Maertens J; Giannoni L; Nicholson E; Collin M; Vaz CP; Metafuni E; Martinez-Lopez J; Dignan FL; Ribera J-M; Nagler A; Folber F; Sanderson R; Bloor A; Ciceri F; Knelange N; Ayuk F; Kroger N; Kersten MJ; Mielke S
Conference publication: BLOOD. 2021;138:2818
Poor Outcome of Patients with COVID-19 after CAR TCell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Spanjaart AM; Ljungman P; De La Camara R; Tridello G; Ortiz-Maldonado V; Urbano-Ispizua A; Barba P; Kwon M; Caballero D; Sesques P; Bachy E; Di Blasi R; Thieblemont C; Calkoen F; Mutsaers PGNJ; Maertens JA; Giannoni L; Nicholson E; Collin MP; Vaz CP; Metafuni E; Martinez-Lopez J; Dignan F; Ribera J-M; Nagler A; Folber F; Sanderson R; Bloor A; Ciceri F; Knelange N; Ayuk FA; Kroeger N; Kersten MJ; Mielke S
Conference publication: BLOOD. 2021;138:485
Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT
Gagelmann N; Eikema D-J; Koster L; Netelenbos T; McDonald A; Stoppa A-M; Kobbe G; Anagnostopoulos A; Van Gorkom G; Deconinck E; Bulabois C-E; Delforge M; Bunjes D; Arcese W; Remenyi P; Itala-Remes M; Thurner L; Bolaman Z; Nabil Y; Mielke S; Labussiere-Wallet H; Hayden PJ; Beksac M; Schonland S; Yakoub-Agha I
Conference publication: BLOOD. 2021;138:1809
Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party
Turki AT; Peczynski C; Penack O; Schoemans H; Socie G; Reinhardt C; Fegueux N; Blaise D; Kroeger N; Mielke S; Cornelissen JJ; Chevallier P; Yakoub-Agha I; Forcade E; Basak GW; Peric Z
Conference publication: BLOOD. 2021;138:1787
Comparative Study of Treosulfan Plus Fludarabine (FT14) with Busulfan Plus Fludarabine (FB4) for Acute Myeloid Leukemia in First or Second Complete Remission: An Analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Gavriilaki E; Sakellari I; Labopin M; Salmenniemi U; Yakoub-Agha I; Potter V; Berceanu A; Rambaldi A; Hilgendorf I; Kroeger N; Mielke S; Zuckerman T; Sanz J; Busca A; Ozdogu H; Savani BB; Giebel S; Bazarbachi A; Spyridonidis A; Nagler A; Mohty M
Conference publication: BLOOD. 2021;138:2901
Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1
Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Salmenniemi U; Mielke S; Chevallier P; Rubio MT; Balsat M; Pioltelli P; Menard A-L; Socie G; Huynh A; Schaap N; Bermudez Rodriguez A; Cornelissen JJ; Yakoub-Agha I; Aljurf M; Giebel S; Brissot E; Peric Z; Nagler A; Mohty M
Preprint: MEDRXIV. 2021
Appearance of IgG to SARS-CoV-2 in saliva effectively indicates seroconversion in mRNA vaccinated immunocompromised individuals
Healy K; Pin E; Chen P; Söderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith E; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Xu X; Akber M; Loré K; Hellström C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Sällberg Chen M
Preprint: MEDRXIV. 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Edvard Smith CI; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S; the COVAXID-collaborator group (shown separately)
Conference publication: BONE MARROW TRANSPLANTATION. 2021;56(SUPPL 1):327-328
Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017
Dillon J; Hayden PJ; Eikema D-J; Koster L; Blaise D; Nicholson E; Potter V; Rabin N; Byrne J; Cornelissen J; Chevallier P; Griskevicius L; Gedde-Dahl T; Arcese W; Collin M; Gribben J; Mielke S; Huynh A; Finke J; Snowden J; Goterris R; Huang H; Beksac M; Schoenland S; Yakoub-Agha I
Conference publication: BONE MARROW TRANSPLANTATION. 2021;56(SUPPL 1):42-43
Impact of SARS-COV-2 on Delivery of Car T Cell Therapy in Europe: A Survey from The Cellular Therapy and Immunobiology Working Party of The EBMT
Ghorashian S; Malard F; Yuksel MK; Hoogenboom J; Mauff K; Urbano-Ispizua A; Kuball J; de la Camara R; Mielke S; Ruggeri A; Chabannon C
Preprint: SSRN. 2021
Appearance of IgG to SARS-CoV-2 in Saliva Effectively Indicates Seroconversion in mRNA Vaccinated Immunocompromised Individuals
Healy K; Pin E; Chen P; Soderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith E; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Xu X; Akber M; Lore K; Hellstrom C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Chen MS
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(5):e213-e217
Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT
Gran C; Wang J; Nahi H; Koster L; Gahrton G; Einsele H; Niittyvoupio R; Edinger M; Beelen D; Ciceri F; Bornhaeuser M; Finke J; de Wreede LC; Ljungman P; Mielke S; Tischer J; Garderet L; Schoenland S; Yakoub-Agha I; Kroeger N
Letter: ANNALS OF HEMATOLOGY. 2020;99(4):899-901
Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation
Luber V; Lutz M; Thiede C; Haferlach C; Duerk HA; Einsele H; Grigoleit GU; Mielke S
Preprint: BIORXIV. 2020
Inhibition of the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells
Shaim H; Sanabria MH; Basar R; Wang F; Daher M; Zamler D; Gumin J; Gabrusiewicz K; Miao Q; Dou J; Alsuliman A; Kerbauy LN; Acharya S; Mohanty V; Banerjee P; Mendt M; Li S; Lu J; Wei J; Fowlkes NW; Gokdemir E; Ensley EL; Kaplan M; Uprety N; Kassab C; Li L; Ozcan G; Shen Y; Gilbert AL; Bdiwi M; Cortes AKN; Liu E; Yu J; Imahashi N; Muniz-Feliciano L; Hu J; Draetta G; Marin D; Yu D; Mielke S; Eyrich M; Champlin R; Chen K; Lang FF; Shpall E; Heimberger A; Rezvani K
Conference publication: TRANSPLANTATION AND CELLULAR THERAPY. 2020;26(3):S286
Allogeneic Stem Cell Transplantation from Two Loci Mismatched (≤6/8) Unrelated Donors in Acute Leukemia: On Behalf of the ALWP of the EBMT
Nagler A; Labopin M; Bruno B; Rambaldi A; Pioltelli P; la Nasa G; Socie G; Mielke S; Ruggeri M; Saccardi R; Platzbecker U; Finke J; Ruggeri A; Savani B; Mohty M
Review: THE LANCET HAEMATOLOGY. 2020;7(2):e157-e167
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Penack O; Marchetti M; Ruutu T; Aljurf M; Bacigalupo A; Bonifazi F; Ciceri F; Cornelissen J; Malladi R; Duarte RF; Giebel S; Greinix H; Holler E; Lawitschka A; Mielke S; Mohty M; Arat M; Nagler A; Passweg J; Schoemans H; Socie G; Solano C; Vrhovac R; Zeiser R; Kroger N; Basak GW
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2020;43(SUPPL 4):58
Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial
Westin J; Tam CS; Borchmann P; Jaeger U; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Andreadis C; Foley SR; Fleury I; Ho PJ; Mielke S; Teshima T; Schuster SJ; Bachanova V; Maziarz RT; Besien KV; Izutsu K; Kersten MJ; Wagner-Johnston ND; Kato K; Corradini P; Han X; Tiwari R; Eldjerou LK; Pacaud LB; Salles GA
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):470-471
Standardized Monitoring of cytomegalovirus-specific Cellular Immunity can Improve Risk Stratification of Recurrent Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation
Wagner E; Teschner D; Wolschke C; Janson D; Schafer-Eckart K; Gartner J; Mielke S; Schreder M; Kobbe G; Kondakci M; Hilgendorf I; von Lilienfeld-Toal M; Klein S; Heidenreich D; Kreil S; Verbeek M; Grass S; Ditschkowski M; Gromke T; Koch M; Lindemann M; Huenig T; Schmidt T; Rascle A; Guldan H; Barabas S; Deml L; Wagner R; Wolff D
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):457-458
Comparison of Immune Cell Response to Cytomegalovirus Proteins Versus Peptides using an IFN-γ Elispot Assay to Monitor cytomegalovirus-specific Immunity after Hematopoietic Stem Cell Transplantation
Wagner E; Teschner D; Wolschke C; Janson D; Schaefer-Eckart K; Gartner J; Mielke S; Schreder M; Kobbe G; Kondakci M; Hilgendorf I; von Lilienfeld-Toal M; Klein S; Heidenreich D; Kreil S; Verbeek M; Grass S; Ditschkowski M; Gromke T; Koch M; Lindemann M; Huenig T; Schmidt T; Rascle A; Guldan H; Barabas S; Deml L; Wagner R; Wolff D
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):467-468
Adenovirus Infections after HCT: Infectious Diseases Working Party Retrospective EBMT Registry Study
Styczynski J; Tridello G; Knelange N; Veelken JH; Socie G; Mielke S; Neven B; Snowden JA; Dalle J-H; Rubio MT; Crawley C; Maertens J; Kuball J; Chevallier P; Michel G; Shaw PJ; Malladi R; Wynn RF; Bertrand Y; Blijlevens N; Jubert C; Gedde-Dahl T; Yakoub-Agha I; Itala-Remes M; Gil L; Cesaro S; Mikulska M
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):23-24
Comparable Outcomes of AML Patients Receiving Haplo-HCT with Thiotepa/Busulfan/Fludarabine Conditioning and Post-Transplant Cyclophosphamide Versus a Matched Unrelated Donor with Fludarabine/Busulfan Conditioning, Regardless of Disease Status
Bazarbachi A; Labopin M; Blaise D; Forcade E; Socie G; Berceanu A; Bulabois CE; Kroger N; Rambaldi A; Ceballos P; Mielke S; Yakoub-Agha I; Savani B; Spyridonidis A; Nagler A; Mohty M
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):109-110
Efficacy, Safety and Feasibility of Treatment of Chronic HCV Infection with Directly Acting Agents (DAAS) in HCT Recipients - EBMT Infectious Diseases Working Party Study
Mikulska M; Tridello G; Knelange N; Santarone S; Di Bartolomeo P; de la Camara R; Cuellar C; Velardi A; Perruccio K; Ljungman P; Mielke S; Zaucha J; Piekarska A; Basak G; Karakulska-Prystupiuk E; Angelucci E; Ciceri F; Stanghellini MTL; Fouillard L; Garcia I; Menconi MC; Blau IW; Nassi L; Nicolini LA; Cesaro S; Styczynski J
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):680
Hepatitis E Virus (HEV) Contaminated Hematopoietic Stem Cell Graft in a Matched Unrelated Donor Transplantation
Boriskina K; Ljungman P; Fernandez LO; Mielke S
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):113-114
Use of Letermovir in Off-Label Indications: Infectious Diseases Working Party EBMT Retrospective Study
Styczynski J; Tridello G; Knelange N; Xhaard A; Socie G; Passweg J; Mielke S; Taskinen M; Blijlevens N; Rodriguez MAB; Solano C; Nikolousis E; Biffi A; Groll A; Junghanss C; Tsirigotis P; Lioure B; Jindra P; Holler E; Galaverna F; Fagioli F; de la Camara R; Mikulska M; Ljungman P
Conference publication: BLOOD. 2019;134:367
The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
Srinagesh H; Ozbek U; Kapoor U; Ayuk FA; Aziz MD; Ben-David K; Choe HK; Defilipp Z; Etra A; Grupp S; Hartwell M; Hexner EO; Hogan WJ; Kitko C; Kowalyk S; Lin J-Y; Major-Monfried H; Mielke S; Merli P; Morales G; Ordemann R; Pulsipher MA; Qayed M; Reddy P; Reshef R; Roesler W; Sandhu KS; Schechter-Finkelstein T; Shah J; Sigel K; Weber D; Wolfl M; Wudhikarn K; Young R; Levine JE; Ferrara JLM
Conference publication: BLOOD. 2019;134:3313
BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society
Saccardi R; Badoglio M; Burman J; Helbig G; Kazmi MA; Mancardi G; Mielke S; Moore J; Muraro P; Sanz J; Sharrack B; Smilowski M; Sormani MP; Snowden JA
Conference publication: BLOOD. 2019;134:4464
Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Post-Transplant Cyclophosphamide
Roy DC; Sanson B-J; Hylton J; Sandler A; Mielke S
Conference publication: BLOOD. 2019;134:4604
Otcome of Two Loci Mismatched (≤6/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study
Nagler A; Labopin M; Bruno B; Rambaldi A; Pioltelli P; La Nasa G; Socie G; Mielke S; Ruggeri M; Saccardi R; Platzbecker U; Finke J; Ruggeri A; Savani BN; Mohty M
Conference publication: CYTOTHERAPY. 2019;21(5):S20-S21
A SINGLE DOSE OF DONOR LYMPHOCYTES DEPLETED OF ANTI-HOST REACTIVE T CELLS (ATIR101) FOLLOWING T-CELL-DEPLETED HAPLOIDENTICAL HSCT IS SAFE AND EFFICACEOUS
Roy D; Walker I; Maertens J; Lewalle P; Olavarria E; Beguin Y; Selleslag D; Wagner E; Boenig H; Mielke S
Conference publication: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(3):s207
Differential Outcomes for Ex Vivo Versus In Vivo Alloreactive T-Cell Depletion Strategies in Haploidentical HSCT
Devine SM; Mielke S; Olavarria E; Tuk B; Meewisse K; Sandler A; Roy D-C
Conference publication: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(3):s202
A Single Dose of Donor Lymphocytes Depleted of Alloreactive T Cells (ATIR101) after Haploidentical HSCT Is Well-Tolerated and Efficacious: Pooled Analysis of Two Phase II Studies
Roy D-C; Walker I; Maertens J; Lewalle P; Olavarria E; Beguin Y; Selleslag D; Wagner E; Boenig H; Bos G; Mielke S
Conference publication: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(3):s342-s343
Clinical Validation of a Novel Elispot-Based in Vitro Diagnostic Assay: Monitoring Cytomegalovirus-Specific Cell-Mediated Immunity and Risk Stratification in Hematopoietic Stem Cell Transplant Recipients
Wagner E; Teschner D; Wolschke C; Janson D; Schaefer-Eckart K; Gaertner J; Mielke S; Schreder M; Kobbe G; Kondakci M; Klein S; Kondakci M; Klein S; Heidenreich D; Kreil S; Hilgendorf I; von Lilienfeld-Toal M; Verbeek M; Grass S; Ditschkowski M; Gromke T; Koch M; Huenig T; Lindemann M; Schmidt T; Rascle A; Guldan H; Barabas S; Deml L; Wagner R; Wolff D
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2019;42:283
The extracellular CTLA-4 domain fusion protein abatacept as salvage therapy in the treatment of severe chronic GvHD after allogeneic stem cell transplantation: a retrospective analysis
Wertheimer T; Fante M; Afram G; Dohse M; Kattner A-S; Hoepting M; Weber D; Holler B; Martinovic D; Neubauer A; Mielke S; Edinger M; Holler E; Herr W; Wolff D
Conference publication: BLOOD. 2018;132:120
Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies
Roy D-C; Walker I; Maertens J; Lewalle P; Olavarria E; Beguin Y; Selleslag D; Wagner E-M; Bonig H; Bos G; Mielke S
Conference publication: BLOOD. 2018;132:3474
Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies
Devine S; Mielke S; Olavarria E; Tuk B; Meewisse K; Sandler A; Roy D-C
Corrigendum: JCI INSIGHT. 2018;3(16):124015
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival (vol 2, e89798, 2017)
Hartwell MJ; Oezbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Woelfl M; Mielke S; Pawarode A; Chen Y-B; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kroeger N; Locatelli F; Morales G; Reshef R; Roesler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JLM
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2018;41:153
Allogeneic donor skin grafts for treatment of refractory ulcers in cutaneous chronic Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation -a retrospective analysis on 7 patients
Lamby P; Mielke S; Grigoleit G-U; Ljungman P; Hilgendorf I; Holler E; Holler B; Weber D; Herr W; Graf S; Prantl L; Dolderer J; Bjornhagen-Safwenberg V; Wolff D
Book chapter: HAPLOIDENTICAL TRANSPLANTATION: ADVANCES AND CONTROVERSIES IN HEMATOPOIETIC TRANSPLANTATION AND CELL THERAPY. 2018;p. 81-88
Photodepletion to Promote Immune Reconstitution Without Graft-Versus-Host Disease After HLA-Haploidentical Transplantation
Roy DC; Mielke S
Book chapter: HAPLOIDENTICAL TRANSPLANTATION: ADVANCES AND CONTROVERSIES IN HEMATOPOIETIC TRANSPLANTATION AND CELL THERAPY. 2018;p. 307-323
Unique Complications and Limitations of Haploidentical Hematopoietic Cell Transplant
Einsele H; Mielke S; Hermann M
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2017;97(3):379-380
Hydroa Vacciniforme-like Skin Lesions in Epstein-Barr-Virus-associated T-cell Lymphoproliferation with Subsequent Development of Aggressive NK/T-cell Lymphoma
Toksoy A; Strifler S; Benoit S; Grigoleit GU; Knop S; Mielke S; Buder-Bakhaya K; Roth S; Goebeler M; Rosenwald A; Geissinger E; Wobser M
Book chapter: ENCYCLOPEDIA OF CANCER. 2017;p. 3487-3489
Peripheral Neuropathy
Mielke S
Review: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2016;82(5):1171-1179
New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease
Lutz M; Mielke S
Book chapter: TRANSPLANT INFECTIONS. 2016;p. 889-908
Adoptive Immunotherapy for Infection Control Using Antigen-Specific Donor-Derived T Cells After Transplantation
Einsele H; Grigoleit G-U; Mielke S
Published conference paper: BONE MARROW TRANSPLANTATION. 2015;50:S51-S54
Immunotherapy for viral and fungal infections
Einsele H; Loeffler J; Kapp M; Rasche L; Mielke S; Grigoleit UG
Book chapter: ENCYCLOPEDIA OF CANCER. 2015;p. 1-3
Peripheral Neuropathy
Mielke S
Review: CURRENT OPINION IN HEMATOLOGY. 2014;21(6):470-475
Diagnosis and treatment of cytomegalovirus 2013
Einsele H; Mielke S; Grigoleit GU
Review: BONE MARROW TRANSPLANTATION. 2014;49(2):163-167
EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT
Rasche L; Kapp M; Einsele H; Mielke S
Letter: INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2012;27(12):1683-1685
Prevention of major infectious complications by pre-emptive enterostomy in patients awaiting allogeneic stem cell transplantation
Kapp M; Grigoleit GU; Dietz UA; Wiegering V; Stuhler G; Schlegel N; Einsele H; Mielke S; Germer C-T; Strauss A
Book chapter: PRÉCIS D’HÉMATOLOGIE ET D’ONCOLOGIE. 2011;p. 820-842
Procédures opérationnelles standards (POS)
Engelhardt R; Engelhardt A; Gärtner F; Mielke S; Frank U; Bertz H
Book chapter: ENCYCLOPEDIA OF CANCER. 2011;p. 2816-2818
Peripheral Neuropathy
Mielke S
Review: BONE MARROW TRANSPLANTATION. 2010;45(11):1579-1586
Role of allo-SCT for CML in 2010
Venepalli N; Rezvani K; Mielke S; Savani BN
Review: BONE MARROW TRANSPLANTATION. 2009;44(12):769-777
Management of relapse after allo-SCT for AML and the role of second transplantation
Savani BN; Mielke S; Reddy N; Goodman S; Jagasia M; Rezvani K
Letter: LEUKEMIA AND LYMPHOMA. 2009;50(12):2071-2074
Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series
Grigoleit GU; Kapp M; Tan SM; Unzicker C; Einsele H; Mielke S; Topp MS; Stuhler G
Book chapter: HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CLINICAL PRACTICE. 2009;p. 409-416
CHAPTER 40 Management of relapse and minimal residual disease after stem cell allotransplantation
Mielke S; Barrett AJ
Book chapter: ENCYCLOPEDIA OF CANCER. 2009;p. 2285-2286
Peripheral Neuropathy
Mielke S
Book chapter: CONCISE MANUAL OF HEMATOLOGY AND ONCOLOGY. 2008;p. 802-822
Standard Operating Procedures (SOP)
Engelhardt R; Engelhardt A; Gärtner F; Mielke S; Frank U
Review: CURRENT OPINION IN ONCOLOGY. 2007;19(6):586-589
Individualized phamacotherapy with paclitaxel
Mielke S
Published conference paper: BLOOD. 2007;110(5):1689-1697
Reconstitution of FOXP3⁺ regulatory T cells (T_regs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease
Mielke S; Rezvani K; Savani BN; Nunes R; Yong ASM; Schindler J; Kurlander R; Ghetie V; Read EJ; Solomon SR; Vitetta ES; Barrett AJ
Conference publication: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):1-2
WTI-specific T lymphocytes participate in the elimination of acute lymphoblastic leukemia following allogeneic stem cell transplantation
Rezvani K; Yong ASM; Price DA; Mielke S; Savani B; Gostick E; Douek D; Barrett AJ
Conference publication: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):78
Regulatory T cell (Treg) reconstitution following T cell depleted allogeneic stem cell transplantation - Kinetics of recovery and relationship with GVHD
Rezvani K; Mielke S; Ahmadzadeh M; Savani B; Kilical Y; Hensel N; Kurlande R; Barrett AJ
Review: EUROPEAN JOURNAL OF CANCER. 2006;42(1):24-30
Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes
Mielke S; Sparreboom A; Mross K
Conference publication: BLOOD. 2000;96(11):359B
Effects of ATG dosage on T-lymphocyte reconstitution after unrelated donor bone marrow transplantation.
Behringer D; Mielke S; Bertz H; Finke J
Published conference paper: GYNAKOLOGISCH-GEBURTSHILFLICHE RUNDSCHAU. 1995;35:157-160
Elevated serum levels of the c-erbB-2 oncogene product p105 in preeclamptic women
Meden H; Mielke S; Wuttke W; Kuhn W
Visa fler

Forskningsbidrag

Center for Cellular Cancer Therapy (C3T)
Swedish Research Council
1 January 2024 - 31 December 2028
SWECARNET - Sweden´s CAR T-cell Competence Network
VINNOVA
31 December 2022 - 1 June 2026
Covid-19 vaccination in immunocompromised individuals: An interdisciplinary framework to gain clinical and mechanistic insight into durable immunity to SARS-CoV-2 infection
Swedish Research Council
1 June 2021 - 31 May 2025
Immune reconstitution and therapy after heamatopoetic stem cell transplantation
Swedish Research Council
1 January 2019 - 31 December 2021
Individual monitoring of minimal residual disease after stem cell transplantation for MDS: the route to reduced relapse rates
Swedish Research Council
1 January 2018 - 31 December 2020

Artiklar

Alla övriga publikationer

Forskningsbidrag

Nyheter från KI

Kalenderhändelser från KI